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SUMMARY 
The increased life expectancy in developed countries has led to a considerable increase in the number of 
pathologies related to the skeletal system with consequent increase in the demand for materials able to repair 
and / or replace damaged tissues. Due to their similarity with the mineral phase of bone tissue, calcium 
phosphates are characterized by excellent biocompatibility and bioactivity and consequently are widely used 
for the preparation of biomaterials able to repair / replace the bone tissue.  The response of the biological 
tissue to synthetic material can be further improved through the functionalization of calcium phosphates with 
ions and biologically active molecules. 
This PhD thesis was addressed to study the interaction between calcium phosphates and several 
functionalizing agents, in order to develop new materials with enhanced biological performance, suitable for 
biomedical applications in the orthopaedic field. The functionalizing molecules taken into consideration 
include several bisphosphonates, namely risedronate, zoledronate, and alendronate, and a molecule from the 
large group of flavonoids, quercetin (3, 3’, 4’, 5, 7-pentahydroxy-flavone). Functionalization of several 
calcium phosphates, namely hydroxyapatite, octacalcium phosphate and anhydrous dicalcium phosphate 
(monetite), was performed following different strategies: direct synthesis and adsorption from solution. 
Characterization of the obtained products allowed to verify the amount of the functionalizing agent 
incorporated into the calcium phosphate, as well as the possible morphological and structural modifications 
induced on the inorganic phase. In particular, the study carried out on risedronate adsorption on four 
hydroxyapatites with different composition provided useful information on the influence of the 
characteristics of the supports on the mechanisms of adsorption and release of the bisphosphonate. The 
materials developed during these three years include also octacalcium phosphate at different content of 
alendronate, as well as octacalcium phosphate at different content of zoledronate, and coatings of mixed 
composition, octacalcium phosphate – calcium alendronate, which were deposited on titanium substrates 
using Maple Assisted Pulsed Laser Evaporation. 
Quercetin functionalized hydroxyapatite was obtained thanks to a modified method of synthesis, which 
implies phase transformation from monetite, as well as through adsorption from solution. Adsorption from 
solution was successfully applied also to load the flavonoid on alendronate functionalized hydroxyapatite, 
monetite and monetite with a partial substitution of strontium to calcium ion. The results of the radical 
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scavenging activity test indicated that quercetin maintained its anti-oxidant properties also when 
incorporated on the calcium phosphates.  
Finally polydopamine coating of octacalcium phosphate and α-tricalcium phosphate was utilized to induce 
reduction of silver ions and decorate the calcium phosphates with silver nanoparticles, thus obtaining new 
composite materials with antimicrobial properties.  
Most of the materials developed in this PhD thesis have been submitted to biological in vitro tests, which 
generally indicated that the peculiar characteristics of the functionalized agents are maintained when 
incorporated into the calcium phosphates, so that they display both the beneficial properties (anti-
osteoporotic and/or anti-inflammatory and/or anti-tumoral and/or anti-microbic) of the functionalizing 
agent(s) and the excellent bioactivity of the inorganic phase. 
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1. Introduction  
 
1.1 Biomimetic Materials 
Biomimetics is the application of biological methods and systems, found in Nature, to the study and design 
of engineering systems and modern technology. Since ancient times, Nature has offered a lot of different 
materials to make tools and weapons but specially, Nature has provided ideas. Looking at how Nature solved 
problems, inventors were able to answer several issues related to everyday life. In modern terms, this 
mankind’s propensity to mimic Nature can be called “Biomimetic Science” that is a multidisciplinary field 
encompassing various research areas including: materials science, materials engineering, biology, 
biochemistry and medicinal chemistry.  
Mimic biological materials is a powerful approach for the synthesis of advanced materials with complex 
shape, hierarchical organization and controlled size, shape and polymorphism under ambient conditions in 
aqueous environments.  In particular the use of a hierarchical structure, a special arrangement of structural 
elements, allows to modulate the mechanical and structural properties that can change from one length scale 
to another. Bone, nacre, tooth enamel, antler, sea sponge spicules, diatoms, are a few examples of materials 
employing inferior components and structural hierarchy to achieve remarkable collections of properties and 
functionalities. 
 This wide variety of materials, which constitute the exo and endo skeletons, as well as other functional 
materials, are built up by Nature through a process called biomineralization. 
In the study of these materials, the main aim is not to simply emulate a particular biological architecture or 
system, but to abstract the guiding principles and ideas in order to exploit them for the preparation of new 
synthetic materials and devices. These ideas promped a rapidly developing research field, which can be 
summarized as bio-inspired or biomimetic materials chemistry. 
At the nanometer scale, biomineralization implies the molecular building of specific and self-assembled 
supramolecular organic systems (micelles, vesicles, etc.) which act as a previously arranged environment to 
control the formation of finely divided inorganic materials, of around 1–100 nm in size. The production of 
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consolidated biominerals, such as bones and teeth, also requires the presence of previously arranged organic 
structures, at a higher length scale (micrometers). 
In this context, the controlled synthesis of inorganic materials with specific morphology is an important 
aspect in the development of new materials for application in many fields such as catalysis, electronics, 
nanocomposites, and of course biomaterials. 
 
 
1.2 Calcium Phosphates for Hard Tissue Repair 
 
The past half century has seen explosive growth in the use of medical implants for hard tissue repair. 
Orthopedic, oral and maxillofacial surgeons are only few examples of medical specialists treating millions of 
patients each year by implanting devices. 
 In addition, an aging population and increasing life expectancy in the developed world mean that our tissues 
and organs are pressed into service longer than they may be able to independently withstand. In this context, 
calcium phosphates are the best candidates to develop new materials thanks to their bioactive and 
biocompatible properties. In particular hydroxyapatite (HA), which resembles the main mineral constituent 
of human hard tissues, has been successfully used clinically for repair of bone defects and augmentation of 
osseous tissues. 
Besides HA, tricalcium phosphates (TCP) (in two different crystallographic phases, α-TCP and β-TCP), 
octacalcium phosphates (OCP), and amorphous calcium phosphates (ACP) are also used. On the other hand, 
calcium phosphates alone have poor mechanical properties, furthermore they hardly fit into a geometrically 
complex defect. To enhance their mechanical properties, calcium phosphates are paired with polymers like 
poly(methyl-methacrylate) (PMMA)[1], poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their 
copolymers [2,3]; as well as natural polymers, such as collagen, fibrin and chitosan. 
Moreover, to improve the bioactivity, synthetic drugs and biomolecules can be adsorbed or covalently 
attached to an implant surfaces, or embedded inside for a slow release after the implantation.  
Typically osteogenic cells and/or osteoinductive growth factors are coupled with bioactive scaffolds [4, 5]. 
Some studies have investigated the bone forming capacities of growth factors loaded synthetic bone 
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substitutes. In terms of growth factors, most research has focused on the use of the bone morphogenetic 
proteins (BMPs) [6]. They are signaling molecules which can induce de novo bone formation at orthotopic 
and heterotropic sites [7]. Current examination of alternatives to grafting techniques suggests three possible 
new approaches to inducing new bone formation: implantation of certain cytokines such as BMPs in 
combination with appropriate delivery systems at the target site [8]; transduction of genes encoding 
cytokines with osteogenic capacity into cells at repair sites; and transplantation of cultured osteogenic cells 
derived from host bone marrow [9].  
In literature a wide range of molecules are reported that are used to functionalize calcium phosphates like 
anticancer drugs [10]; insulin [11]; analgesic drugs [12], and antibiotics [13]. 
Unfortunately, even with all this kind of molecules and strategies, we still really know very little about the 
mechanism used by organisms to form their superior materials. In addition, all therapies which are based on 
complex biomolecules are costly and difficult to regulate. Better biomaterials for bone substitution and are 
not still developed, and this fact makes this research field exciting and still in progress.  
 
1.2.1 Bone tissue  
Skeleton, and consequently bone, has a primary function which is that of structural support of the 
mammalian body and constantly remodeling in response to the applied stresses.  
In addition to this structural function, bone is also important for internal organ protection, muscle support 
and regulation of the calcium ions concentration through the ongoing resorption and formation of new 
mineral, regulated by two kinds of cells: osteoblast and osteoclast.  
Bone is a dynamic, highly vascularized tissue that is formed from a composite of 70% mineral (mostly 
nanoscale HA crystals) and 30% organics (including collagen, glycoproteins, proteoglycans, and 
sialoproteins) by dry weight [14]. 
The mineral and the organic part are arranged in a complex architecture with several hierarchical levels, from 
nanometer to macroscopic scale, which provides bone unique structure and properties.  
The basic building block of bone, for subsequent higher order architectures, is the mineralized collagen 
fibril. It is composed of the fibrous protein collagen which constitutes the main component of a three-
dimensional matrix into which, and in some cases onto which, the mineral forms. The mineral in this family 
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of materials is dahllite, also known as carbonated apatite (Ca5 (PO4, CO3)3 (OH)) [15]. The third major 
component is water [16].  
 
Table1 Organic components of bone [15] 
NAME FUNCTION IN BONE MINERALIZATION 
 
 
Collagen 
 
 
 
 
Structural protein found in many tissues. 
 
 
Bone sialoprotein (BSP), Osteonectin (ON), 
Chondroitin sulfate (ChS) and Keratan sulfate 
 
Acid protein with poly(glutamic acid) run and RGD binds calcium 
glycoproteins that may either nucleate or block HA mineralization 
large molecular weight, sulfated glycosaminoglycans that are found 
in cartilage and bone tissues. 
 
 
 
 
Osteocalcin(OC), Biglycan and Decorin 
 
Inhibits bone formation; does not appear to affect HA 
mineralization proteoglycans that bind to type I collagen and are 
involved in assembly of bone matrix; Decorin specifically interacts 
with d and e bands of collagen; Biglycans consist of leucine-rich 
repeats and two glycosaminoglycans; these protein also interact 
with thrombospondin and fibronectin. 
 
 
 
Thrombospondin and Fibronectin 
 
 
 
 
Matrix glycoproteinsthat bind to integrins and ECM components 
(collagen, fibrin, etc.) 
 
The first level of hierarchy consists of the molecular components: water, HA, collagen, and other proteins. 
The crystals of HA are plate-shaped and are among the smallest known biological crystals (30-50 nm long, 
20-25 nm wide, and 1.5-4 nm thick). Non-collagenous proteins (NCPs) are also present but make up 10% or 
less of the total protein content in the bone matrix. The specific functions of the NCPs are still not 
completely understood, but some studies report that they influence crystal nucleation and growth and they 
also play roles in cell signaling and ion homeostasis [17]. 
The second level is formed by the mineralization of collagen fibrils. This platelet-reinforced fibril composite 
is described as containing parallel plate-like HA crystals [16] with their c-axis aligned with the long axis of 
the fibril [18]. 
The third level of hierarchy is composed of arrays of these mineralized collagen fibrils. These fibrils are 
rarely found isolated but rather almost always associated as bundles or in other arrangements, often aligned 
along their long axis.  
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The fourth level is the patterns of arrays that are formed. These include parallel arrays, woven arrangements, 
plywoodlike structures, and radial arrays. 
Cylindrical structures called osteons make up the fifth level. Osteons are formed by a significant cellular 
activity and remodeling; osteoclasts resorb bone and form a tunnel, and osteoblasts subsequently lay down 
lamellae in stacked layers until only a small channel (Haversian canal) is left behind. These channels serve as 
a conduit for nerves and blood supply to the bone cells. The metabolic substances can be transported by the 
intercommunicating systems of canaliculi, lacunae, and Volkman’s canals, which are connected with the 
marrow cavity. The various interconnecting systems are filled with body fluids and their volume can be as 
high as 19%.  
The sixth level of bone organization is the classification of osseous tissue as either spongy (trabecular or 
cancellous) or compact (cortical). Cancellous bone (also called trabecular or spongy bone) is extremely 
porous (75-95% porosity), providing space for marrow and blood vessels, but has much lower compressive 
strength. Cortical bone is the dense outer layer (5-10% porosity) that allows most of the support functions of 
bone. The seventh level is simply the whole bone on the macroscopic scale, incorporating all of the lower 
levels of hierarchy. 
 
Figure1 Structure of the bone, on the right a focus on osteon structure (www.mhhe.com) 
 
The inorganic component is a nanocrystalline solid with apatite structure and the chemical composition of a 
carbonated, basic calcium phosphate, hence it can be termed a carbonate-hydroxy-apatite. The benefits of the 
inorganic component are toughness and the ability to withstand pressure.  
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Besides the main ions Ca
2+
, PO4
3−
 and OH
−
, the composition of biological apatites always includes CO3
2−
 at 
∼4.5%, and also a series of minority ions, including Mg2+, Na+ , K+ , Cl− and F− .  
The apatite structure can hosts carbonate in two positions: the OH
−
 sub-lattice producing so-called type A 
carbonate apatites or the [PO4] 
3−
 sub-lattice called type B apatites. 
Small dimensions and low crystallinity are two distinct features of biological apatites which, combined with 
their non-stoichiometric composition, inner crystalline disorder and presence of carbonate ions in the crystal 
lattice, explain their special behavior. In fact a younger, less crystalline tissue can develop and grow faster, 
while storing other elements that the body needs during its growth. Biological apatites are calcium-deficient; 
hence their Ca/P ratio is always <1,67, the value characteristic of stoichiometric apatite. 
As shown before, bone maintains a dynamic state, through a process termed remodelling due to the 
coordinated actions of bone resorption and synthesis, mediated by osteoclasts and osteoblasts, respectively. 
In any case, the activity of bone cells is highly regulated and stimulated by hormones and cytokines. Steroid 
hormones act on various cell types to regulate development, cell proliferation and cell differentiation. 
Osteoblasts are mononuclear cells of mesenchymal origin that are responsible for formation of the osteoid, 
the organic portion of the bone tissue. In addition to osteoid secretion, osteoblasts are also involved in the 
mineralization process. These cells are believed to regulate the local calcium and phosphate concentrations to 
promote apatite mineralization. [19, 20] 
As osteoblasts become trapped in the secreted matrix, they terminally differentiate into osteocytes [21], 
mature and interconnected cells which are responsible to be signaling for matrix resorption or formation in 
response to mechanical stress [22]. 
Osteoclasts remove bone tissue by a process known as “bone resorption” [23, 24]. The actin cytoskeleton of 
the osteoclast reorganizes into a ring known as the “sealing zone”; the cell membrane forms a “ruffled 
border” at the contact with the bone tissue to facilitate dissolution of the apatite mineral followed by 
hydrolysis of the collagen-rich organic matrix [23]. Vacuolar proton pumps cause demineralization of the 
bone matrix by acidification to a pH of∼4.5 [24].The organic portion of the matrix is further broken down by 
lysosomal cysteine proteases [25] and matrix metalloproteases (MMP) [23].  Finally, the degraded 
extracellular materials are removed from the resorptive lacuna, shuttled into the extracellular space and 
ultimately into the blood [23]. 
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1.2.2 Calcium Phosphates of biological interest 
Calcium phosphates exhibit a wide range of possible applications, which span from their use as catalysts, as 
starting materials in the preparation of phosphatic fertilizers, as columns in chromatographic separation and 
as stabilizers for plastics, up to the biomedical field. 
The biological interest is due to the fact that calcium phosphates are the main constituent of bone and teeth 
and consequently, being biocompatible and bioactive, they are widely used as biomaterials for the repair and 
replacement of bone tissue. The interest is not only for hydroxyapatite, which for composition and structure 
is often equated to biological apatite, but even for other more resorbable calcium phosphates, like amorphous 
calcium phosphate (ACP), α-tricalcium phosphate (α-TCP), β-tricalcium phosphate (β-TCP), octacalcium 
phosphate (OCP), dicalcium phosphate dihydrate (DCPD), dicalcium phosphate anhydrous (DCPA), that can 
be easily converted into nanocrystalline apatite [26]. 
 
Table 2 Calcium Ortophosphates 
COMPOUND FORMULA SPACE GROUP Ca/P 
DCPD CaHPO4*H2O Monoclinic Ia 1.00 
DCPA CaHPO4 Triclinic P-1 1.00 
OCP Ca8(HPO4)2(PO4)4*5H2O Triclinic P-1 1.33 
α-TCP α-Ca3(PO4)2 Monoclinic P21/a 1.50 
β-TCP β-Ca3(PO4)2 Rhombohedral R3Ch 1.50 
HA Ca10(PO4)6(OH)2 Hexagonal P63/m 1.67 
 
 
Most calcium orthophosphates are sparingly soluble in water, but all dissolve in acids; in particular, the 
lower is the Ca/P ratio the more acid and soluble is the calcium phosphate phase.  
Further, the presence of organic molecules can affect the crystallization process, complicating the detection 
of intermediate phases [27]. 
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Hydroxyapatite (HA) is the most thermodynamically stable and less soluble phase and it is preferentially 
formed under neutral or basic conditions. In more acidic solutions, phases such as brushite (DCPD) and 
octacalcium phosphate (OCP) are often encountered. 
In biological tissues, DCPD and OCP are usually detected only during pathological calcification, where the 
pH is often relatively low. In normal in vivo calcifications, these phases have not been found, suggesting the 
involvement of other precursors or the formation of an initial amorphous calcium phosphate phase (ACP), 
followed by transformation to apatite [28]. 
The stability of calcium phosphate (CaP) phases in contact with aqueous solutions can be understood in 
terms of a typical solubility phase diagram in which solubility isotherms are expressed as plots of (log 
TcaTp) as a function of pH (Figure 2). Here, Tca and Tp are the total molar concentrations of calcium and 
phosphate, respectively. Figure 2 has been constructed on the assumption that the solution contains equal 
total molar concentrations of calcium and phosphate ions at an ionic strength of 0.1 M. The position of the 
curves and the singular points in Figure 2 will change if the ionic strength of the background electrolyte is 
varied. It can be seen that, at pH above 4.0, HA is the most stable phase, followed by TCP and OCP. At pH 
values lower than 4.0, DCPD is more stable than HA. The variations in solubility with pH imply that a phase 
exposed to acidic conditions may be covered by a surface coating consisting of a more acidic calcium 
phosphate phase [29]. 
Moreover, the kinetic factors are fundamental for determining which crystalline phases will be formed, with 
respect to the others in a supersaturated solution. In fact, HA formation evolves through the formation of 
intermediate products which are thermodynamically metastable but kinetically favoured. 
The influence of pH on the formation of calcium phosphates is linked to the properties of phosphate 
containing solutions. Due to the triprotic equilibria in these systems, variations in pH alter the relative 
concentrations of the four protonated forms of phosphoric acid and thus both the chemical composition and 
the amount of the CaP that forms by direct precipitation. This complex equilibrium makes the control and 
prediction of CaP precipitation very difficult [30]. 
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Figure2 Solubility phase diagram of various calcium phosphates and relative Ca/P ratio [31] 
 
 
1.2.2.1 Hydroxyapatite  
 
The name apatite is given to a class of inorganic compounds whose general formula can be written as 
M10(XO4)6Y2: where M is generally a bivalent cation like Ca
2+
, Sr
2+
, Ba
2+
, Cd
2+
 o Pb
2+
, but even monovalent  
(Na
+
, K
+
) and trivalent  (Al
3+
) cations can be hosted in the structure. The term XO4 indicates trivalent anions 
like PO4
3-
, VO4
3-
 o AsO4
3-
, even if anions with different charge (SiO4
4-
, CO3
2- 
e SO4
2-
) can enter in the 
elementary cell. Finally Y is referred to a monovalent anion like F
-
, Cl
-
, Br
-
 or OH
-
 . 
Hydroxyapatite (Ca10(PO4)6(OH)2) is the most stable and insoluble calcium phosphate (CaPs) and is the most 
similar to the inorganic component of bone from a chemical and structural point of view. The known 
crystalline forms of hydroxyapatite are two: the monoclinic one, space group P21/b, and the hexagonal one, 
space group P63/m; but only the hexagonal phase have a practical interest because the monoclinic form is 
destabilized by the presence of even small amounts of foreign ions [31]. 
The P63/m space group has three kinds of vertical symmetry elements: (1) six-fold screw axes passing 
through the corners of the unit cells which are equivalent to a three-fold rotation axis with a superimposed 
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two-fold screw axes; (2) three-fold rotation axes passing through 
2
/3, 
1
/3, 0 and 
1
/3, 
2
/3, 0; and (3) two fold 
screw axes passing through the mid points of the cell edges and its centre. There are also mirror planes 
perpendicular to the c-axis at z = ¼ and ¾, and numerous centres of symmetry. 
The basic apatite hexagonal structure exhibits approximate lattice parameters a = 9.43 Å and c = 6.88 Å 
α=β=90° γ= 120° with two formula units per cell [32]. This is the reason why a double formula is often used 
[Ca10(PO4)6X2]. The values often depend on the mode of preparation because of the frequent non-
stoichiometry. The hydroxyapatite stoichiometry is characterised by a molar ratio Ca/P equal to 1.67. 
The structure can be roughly described as an assembly of tetrahedral phosphate PO4
3-
, among which are 
placed the calcium ions in two independent crystallographic sites, crossed by parallel channels filled by OH
-
 
ions and oriented along  the crystallographic c-axis (Figure 3). 
 
 
Figure 3 A view of the HA structure along the c-axis. Black lines connect Ca(I) columns in hexagonal networks. Cyan and 
magenta triangles connect staggered Ca(II) atoms lying in the same plane but at different height with respect to the c-axis 
[26]. 
 
The first crystallographic site for calcium ions is called columnar site and it is indicated as Ca(I).  In the 
columns, Ca
2+
 ions, which account for two-fifths of the Ca
2+
 ions in the structure, are spaced by one-half of 
the c-axis parameter along the three-fold axes at 
2
/3, 
1
/3, 0 and 
1
/3, 
2
/3, 0.  
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The second crystallographic site for the calcium ions is called triangular site. The calcium ions Ca(II) form 
two triangles rotated by 60° from each other about the c-axis;  the OH
-
 ions are located at the center of the 
triangles. 
Among the 10 cations, the 4 Ca(I)s are tightly bonded to 6 oxygens and less strongly to the other 3 oxygens 
(mean Ca(I)–O distance 0.255 nm), whereas the 6 Ca(II) atoms are surrounded by 7 oxygens (mean Ca(II)–O 
distance 0.245 nm). Ca(I) atoms are strictly aligned in columns and any small change in the metal–oxygen 
interactions affects the entire lattice. However, the Ca(II) atoms belonging to consecutive layers are 
staggered, allowing random local misplacements without compromising the whole structure. As a 
consequence, cations smaller than Ca or also low concentrations of slightly larger cations are preferably 
accommodated in site Ca(I) where stronger interactions are present, while larger cations should be 
accommodated in position Ca(II), even at high concentrations. 
 
 
Figure 4 View of the atomic structure of hydroxyapatite as a stand-in for bioapatite. Viewed (A) down the c-axis and (B) 
perpendicular to the c-axis [38]. 
 
The literature reports a variety of syntheses of HA that, although differing in terms of the detailed conditions, 
essentially follow two methods. The first one consists in the stoichiometric titration of a calcium hydroxide 
slurry with phosphoric acid up to neutrality [33]. In the second one, the precipitation method, a solution of 
ammonium or sodium monohydrogen phosphate is added dropwise to a calcium solution (generally calcium 
nitrate or acetate) or vice versa [34,35]. Both methods yield good crystalline products when carried out at 
100°C. Lower temperature provokes an increase in the amount of amorphous material and/or decrease in 
crystallinity. The titration method is performed in a basic environment, whereas the precipitation method 
often implies addition of ammonia or sodium hydroxide to maintain a basic pH (>9) during precipitation. A 
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further factor that influences crystallinity and crystal dimensions is the reaction time: short reaction times 
provide nanocrystals and/or amorphous products, whereas crystal dimensions and crystallinity increase with 
increasing reaction time [26]. 
 
1.2.2.2 Octacalcium Phosphate 
 
Octacalcium phosphate (OCP) has a significant biological relevance due to its role as a possible precursor 
during the formation of carbonated apatite in the hard tissues of vertebrates. Thus understanding the growth 
of OCP and its hydrolysis provides useful information for understanding the processes of mineralization in 
bones and teeth. 
In addition, OCP has been found as a constituent in dental calculus, in pathological calcifications [36] and in 
a crystal of calcifying dentine together with apatite [37]. 
OCP crystallizes in a triclinic structure [39], space group P 1  and unit cell a = 19.692 Å, b = 9.523 Å, c = 
6.835 Å, α = 90.15°, β = 92.54° and γ = 108.65°.  
OCP has a remarkable structural similarity to HA due to its layered structure involving apatitic and hydrated 
layers [40-43], parallel to the (100) face. It is generally assumed that, in solutions, the hydrated layer of the 
(100) face is the most likely exposed to solution [27]. 
The apatitic layer (1.1 nm thick) consists of phosphate ions inter-dispersed with Ca
2+
 ions resembling the 
ions positions in the structure of apatite. 
 
 
 
  
 
 
The hydrated layer of the OCP unit cell may form an interphase between HA and the surrounding solution 
[44]. If this occurs, the epitaxial intergrowth of OCP and HA is favored. 
Hydrated layer 
Apatitic  layer 
(010) 
(100) 
Figure 5 Layered structure of Octacalcium phosphate 
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The hydrated layer (0.8 nm thick) consists of more widely spaced phosphate and calcium ions with a slightly 
variable number of water molecules between them. Six of the Ca
2+
 ions and two of the phosphate ions are in 
the apatitic layer, the other two Ca
2+
 ions and one phosphate ion are in the hydrated layer and the remaining 
three phosphate ions lie at the junction of the apatitic and hydrated layers. The phosphate ion in the hydrated 
layer and one at the junction between the layers are protonated.  
 
1.2.2.3 Dicalcium Phosphate Anhydrous  
 
Dicalcium phosphate anhydrous (Monetite or DCPA) at room temperature crystallizes in the triclinic form, 
space group  P-1 with lattice parameters a=6,9160Å,b=6,6190Å,c=6,9460 Ǻ,α=96,18°,β=103,82°, γ= 88,34°.  
DCPA is less soluble than the hydrated form, DCPD, under all conditions of normal temperature and 
pressure and thus it might be expected to be of more frequent occurrence. However, its slow rate of crystal 
growth relative to DCPD [44] might explain why DCPD forms instead of DCPA, even though it is less 
stable. This observation again underlines the importance of kinetic factors in determining which phase is 
formed in the Ca(OH)2-H3P04-H20 system. 
There are four formula units per unit cell of DCPA. Double chains of •••Ca P04Ca P04 Ca P04 CaP04••• 
(Figure 6), extending along the a-axis, are linked together in the 6-axis direction by Ca-O bonds to form 
distorted sheets of atoms approximately in the (001) plane: the centre of symmetry produces another sheet 
below this in the c-axis direction. 
 
 
Figure 6 Double chain of Ca2+ ions and phosphates ions that characterize the DCPA structure 
 
Calcium(black) 
Phosphorus(red) 
Oxigen (yellow) 
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1.2.2.4 Alpha-Tricalcium Phosphate  
 
Alpha-tricalcium phosphate (α-TCP) is used as the main constituent of calcium phosphate bioactive bone 
cements and biphasic calcium phosphate ceramics. Its hydrolysis and conversion into apatite phase may play 
an important role in new bone formation in vivo. 
 Αlpha-TCP is highly reactive in aqueous systems and can be easily hydrolysed to a mixture of other calcium 
phosphates. Alpha-TCP crystallizes in a monoclinic structure, space group P21/a and unit cell a = 12.887(2) 
Å, b = 27.280(4) Å, c = 15.219(2) Å and β = 126.20(1)°, with 24 formula units per unit cell [45]. There is an 
approximate subcell with a b-axis parameter of b/3 (9.09 Å) that contains 8 formula units, which corresponds 
to the unit cell reported earlier [46]. 
The structure of α-TCP is constituted of columns of Ca2+ and PO4
3-
 ions which run parallel to the c-axis.  
The α-TCP approximate subcell b-axis parameter of 9.09 Å corresponds to the apatite a-axis parameter, 
whilst half the c-axis parameter of α-TCP (7.6 Å) corresponds to the c-axis parameter of apatite. The apatite 
structure can so be derived from α-TCP by replacing the cation-cation columns at the corners of the apatite 
cell by anion columns (OH
-
 in hydroxyapatite, F
-
 in fluoroapatite…). 
 
 
Figure 7 (A) α-TCP unit cell projected on the (a,b) plane and (B) projected onto the (b,c) plane. Tetrahedra represent PO4 
groups and light balls denote Ca atoms. (C) β-TCP unit cell projected on the (a,c) plane. Tetrahedra represent PO4 groups, 
small balls designate Ca atoms and big balls are for the Ca’s with half occupancy [48]. 
 
 
(C) (B) (A) 
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1.2.2.5 Beta-Tricalcium Phosphate  
 
Beta-Tricalcium Phosphate (β-TCP) crystallizes in the rhombohedral space group R3c, and its unit cell 
contains 21 [Ca3(PO4)2] formula units [47]. There are three types of crystallographically nonequivalent PO4
3-
 
groups located at general points of the crystal, each type with different intra tetrahedral bond lengths and 
angles.  
β-TCP unit cell contains 21 formula units, 273 atoms in total, with one Ca site (multiplicity 6) only half 
occupied, implying a structure with three Ca vacancies per unit cell [48]. 
β-TCP can be obtained only at high temperature, by solid-state reaction or by thermal conversion of other 
phosphates, and it is stable up to 1125 °C (Above 1125°C β-TCP converts into α-TCP) [31]. 
β-TCP has been identified during pathological calcifications, such as dental calculi and renal stones, but it 
has not been observed in enamel, dentin, or bone [49]. The ideal β-TCP structure contains calcium ion 
vacancies that are too small to accommodate a calcium ion but allow for the inclusion of magnesium ions, 
which thereby stabilizes the structures [47]. The most common one (whitlockite), formed under 
physiological conditions, is stabilized by magnesium ions and is not detected physiologically, unless 
magnesium ions are present [47]. 
 
1.3 Functionalization of CaP with bioactive ions and  molecules. 
The possibility to change the structural and chemical properties of these materials, through ion substitution 
and/or adsorption of bioactive molecules, can extend the range of potential practical applications as 
bioceramic, catalyst, liquid-chromatographic column, lighting materials and chemical sensors. In fact, even 
small amounts of ionic substitution have been shown to have very significant effects on thermal stability, 
solubility, osteoclastic and osteoblastic response in vitro, degradation and bone regeneration in vivo. The 
adsorption of bioactive molecules on CaPs can be used to modify characteristics, such as surface 
morphology, microstructure, composition, and properties, with the purpose of enhance cellular response and 
for drug delivery.  
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1.3.1 Zinc  
Zinc is an important metal in the normal growth and development of the skeletal system, where it has been 
shown to display an inhibitory effect on osteoclast differentiation and a promotion of osteoblast activity [50]. 
Zn ion is one of the most effective metal ions in inhibiting HA crystal growth [51, 52]. Nonetheless, it can be 
quantitatively incorporated into HA lattice by direct synthesis under mild conditions [53-55], through 
hydrothermal technique at 200 °C [56] and by means of a sol–gel process  [57]. 
The lattice parameters of Zn-HA are related to the difference in ionic radius between Zn
2+
 (0.074 nm) and 
Ca
2+
 (0.099 nm). 
Density function theory calculations confirm that Zn prefers the Ca(II) site over the Ca(I) site for the 
substitution, and favors tetrahedral coordination with significant local structural distortion. 
In the tetrahedral coordination, one of the four oxygen atoms bonded to Zn is from the nearest hydroxyl 
group and three are from the adjacent phosphate groups. This arrangement causes a reduction in the a lattice 
parameters from 0.9488 nm to 0.9319 nm , whereas the Zn-O(OH) distance is 0.202 nm compared to 0.269 
nm of ideal distance in HA [58]. 
The reported substitution limit of Zn in HA varies between 15% and 25% [59,60],  and both Ca/P and 
(Ca+Zn)/P ratios decrease on increasing Zn content and, as a consequence, stoichiometry is no longer 
maintained [61]. 
 
1.3.2 Silver Nanoparticles 
Silver nanoparticles find use in many fields; the major applications include their use as catalysts, as optical 
sensors, in textile engineering, in electronics, in optics, and most importantly in the biomedical field as a 
bacteriostatic and as a therapeutic agent. The size of these nanoparticles is in the range of 1 and 100 nm. The 
properties of Ag nanoparticles depend on their mean size, as well as on their structure, shape and size 
distribution. Generally, specific control of shape, size, and size distribution is often achieved by varying the 
synthesis methods, reducing agents and stabilizers [62-64]. 
The stabilization can be obtained in two ways, electrostatic and steric. Electrostatic stabilization is achieved 
by the coordination of anionic species, such as halides, carboxylates or polyoxoanions, to metal particles. 
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This results in the formation of an electrical double layer (really a diffuse electrical multilayer), which causes 
coulombic repulsion between the nanoparticles. Steric stabilization is achieved by the presence of bulky, 
typically organic materials (polymers) that, due to their bulk, hinder nanoparticles aggregation.  
 
 
 
 
 
 
 
 
 
Figure 8 Electrostatic and steric stabilization of nanoparticles. 
 
Currently, many methods have been reported for the synthesis of Ag-NPs by using chemical, physical, 
photochemical and biological routes [65]. 
The most widely accepted mechanism of silver biosynthesis is the presence of the nitrate reductase enzyme, 
that might be responsible for the bioreduction of silver ions and the subsequent formation of silver 
nanoparticles to metallic silver (Ag+ to Ag0) [66].  
The physical approach utilizes several methods such as evaporation/condensation [67,68] and laser ablation 
[69-71]. 
In the chemical approach the metal ions in solution are reduced in conditions favoring the subsequent 
formation of small metal clusters or aggregates [72-74]. Chemical reduction is the most frequently applied 
method for the preparation of AgNPs as stable, colloidal dispersions in water or organic solvents. Commonly 
used reductants are borohydride, citrate, ascorbate and elemental hydrogen [75, 76]. The reduction of silver 
ions (Ag
+
) in aqueous solution generally yields colloidal silver with particle diameters of several nanometers. 
Initially, the reduction of various complexes with Ag+ ions leads to the formation of silver atoms (Ag
0
 ), 
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which is followed by agglomeration into oligomeric clusters. These clusters eventually lead to the formation 
of colloidal Ag particles. 
 
1.3.3 Flavonoids  
 
Flavonoids are a ubiquitous group of polyphenolic substances which are present in most plants, concentrated 
in the seeds, fruit skin or peel, bark and flowers [77]. More than 4000 different flavonoids have been 
identified to date, making them the largest group of plant chemicals. Many fruits and vegetables, especially 
buckwheat, apple and onion, contain flavonoids [78]. 
Quercetin is the most biologically active and common dietary flavonoid, and is generally used as a dietary 
supplement. 
The carbon atoms in flavonoid molecules are assembled in two aromatic rings, commonly denoted as A and 
B, which are connected by a three-carbon “bridge”: C6–C3–C6, thus forming a diphenyl-propane structure 
with the central unit being a benzo-α-pyrone (chromone). Multiple hydroxyl groups, sugar, oxygen, or 
methyl groups are attached to this core structure. 
 Depending on the oxidation state and on the position of the heterocyclic ring, flavonoids are classified as 
(Figure 9): 
 
– ring B in position 2: flavanones, flavones , flavonols , antocianine; 
– ring B in position 3: isoflavones. 
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Figure 9 Classification of flavonoids based on the position of B ring [88] 
 
Scientific studies conducted in the last few years generated a growing interest in the potentially important 
role of flavonoids in maintaining human health. The pharmacological effects are related to the anti-oxidant 
activity of flavonoids, arising from their ability to scavenge free radicals. Radical scavenging by flavonoids 
occurs via electron donation from the free hydroxyls on the flavonoid nucleus with the formation of a less 
reactive flavonoid aroxyl radical, which is stabilized by resonance and therefore plays only a moderate role 
in the propagation of radical- induced damage in biological systems. 
In particulary, quercetin has been reported to exhibit antibacterial activity [79] and to reduce bone resorption 
in vitro via the direct targeting of the mature osteoclasts by a mechanism involving estrogen receptors (ERs) 
[80,81]. 
Moreover, it inhibits mRNA expression of osteoclast related genes [82] and osteoclast differentiation [83, 
84]. 
Being pigments responsible for the color of leaves, herbs and petals, flavonoids strongly absorb ultraviolet 
(UV) radiation. Therefore UV–Vis spectroscopy remains the main tool for structural analysis of flavonoids. 
Typically, the major absorption maxima observed in the UV–Vis spectrum. are two: the absorption 
maximum observed in the range 240–285 nm is referred to as the band II and the one between 300–400 nm 
as the band I. In general terms, absorption band II may be considered as originating from π π * transitions 
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in the A ring, a benzene system, whereas the absorption band I is attributed to transitions in the B ring, a 
cinnamoyl system (Figure 10). The position of band I in flavones is between 304–350 nm, while flavonols 
absorb in the range 352–385 nm. Highly oxygenated flavones and flavonols tend to absorb at longer 
wavelengths than those with fewer oxygen substituents. Methylation or glycosylation of the hydroxyl groups 
on the flavonoid nucleus usually results in hypsochromic shifts, predominantly of band I [85]. 
 
 
 
 
 
Figure10 Benzoyl and cinnamoyl group of quercetin and relative Uv-Vis absorbance values 
 
 
Due to their specific chemical structure, flavonoids easily chelate metal ions and create complex compounds. 
There are three domains that can likely interact with metal ions, the 3',4'-dihydroxy group located on the B 
ring, the 3-hydroxy or 5-hydroxy and the 4-carbonyl groups in the C ring. Generally, the chelating properties 
of flavonoids toward metal ions have been attributed to the presence of the 3- or 5-hydroxypyran-4-one, 
rather than the ortho-hydroxyl groups in the B ring [86]. 
Thanks to this ability they are able to prevent metal-mediated generation of free radicals and, accordingly, 
may protect the potential biological targets from oxidative stress. Thus, the overall anti-oxidant action of 
flavonoids appears to be a combination of a direct reaction with free radicals and of a chelation of the metal 
ions responsible for the production of reactive oxygen species. 
Cinnamoyl 
Band I =372 
Benzoyl Band 
II= 256 nm 
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The pH has an important influence on Flavonoids, which are weak polybasic acids that tend to protonate. 
Therefore, pH has a strong impact on complex formation with metal ions [87]. For example, pH values 
around 6 favor deprotonation of flavonoids and, consequently, more complex species. On the other hand, at 
higher pH values, metal ions are often involved in side reaction (hydrolysis) and hydroxo-complexes are 
formed [88]. 
Complexation with flavonoids as unidentate or bidentate ligands leads to the formation of complexes that 
contain protons in addition to the metal ion and ligand (so-called protonated complexes) which tend to 
dissociate at pH values higher than 6. In this case, the dissociations of the protonated complexes or the 
formation of new complexes with different stoichiometric composition could be observed. Hence, the 
absorption spectra exhibit a bathochromic shift, as shown by Malesev et al. 2007 for the titanyloxalato-
quercetin complex [88]. 
 
1.3.3.1 Quercetin  
 
Quercetin (IUPAC 3,3',4',5,7-pentaidrossiflavone) belongs to the flavonols group and it is the agliconic 
component of various glicosides, like rutin and quercitrin.  
 
 
Figure 11 Molecular structure of quercetin: (A) ring lettering and atom numbering convention; (B) oxygen–oxygen distances 
that roughly match structural Ca–Ca distances in HA [93]. 
 
The biochemical activity of quercetin depends on the structure and the relative orientation of the rings and of 
the hydroxyl groups inside the molecule. The B ring hydroxyl configuration mostly determines the 
antioxidant effect, while the activity of the other hydroxyl position is not yet clear [89]. 
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The torsion angle of B ring compared to all the other part of the molecule strongly influences the antioxidant 
activity. The planarity allows the coniugation, the electronic dislocation and a consequent increase in 
stability of the phenoxide radical.  
The removal of –OH in position 3 deletes the coplanarity and the coniugation, thus compromising 
completely the quercetin antioxidant activity in the oxidation of linoleic acid [90]. 
It has been assumed that the hydroxyl group of B ring forms a hydrogen bonding with the –OH group in 
position 3, aligning the B ring with the heterocycle and the A ring. Deleting this hydrogen bonding 
compromised the electron delocalization property.  
The molecular geometry is defined by two effects that act in oppositely: the hydrogen atom repulsion in 
ortho position on the B ring, that would bring the molecule in a staggered position, and a coniugation effect 
that tends to bring the phenyl in the chromone plan.  
The data obtained by X-ray analysis show that quercetin crystallizes in the spatial group P1, with two water 
molecules for unit cell [91]. With five hydroxyls groups and one carbonyl, quercetin has a huge possibility to 
create intra- and intermolecular hydrogen bonds.  
Quercetin contains two crystallization water molecules, which take part in a wide network of hydrogen 
bonds across the crystal. The hydroxyl groups in position 3 and 5, in fact, are involved in intra-molecular 
hydrogen bonds with the carbonyl oxygen in position 4 [92]. This oxygen atom takes part to the formation of 
a dimer obtained through the inter-molecular hydrogen bond with the hydroxyl group in position 5 of the 
adjacent molecule. Quercetin, hence, has a quasi-planar structure and tends to form highly oriented 
nanostructure in suspension.  
Quercetin molecular dimensions are similar to those between the  Ca
2+ 
ions on the (110) face of HA. 
Moreover quercetin has a negative charge on the molecular plane and so it could be attracted by the calcium 
ions present in the HA structure. On this basis, it has been suggested that quercetin could act as soft template 
in the regulation of crystal growth direction of HA [90]. 
 
1.3.4 Polydopamine  
Dopamine (DA) is a neurotransmitter which is found in animal/humans and has a chemical structure similar 
to 3,4-dihydroxy phenylalanine (DOPA). 
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DA contains catechol and amine functional groups that can self-polymerize in weak alkaline solution to form 
polydopamine (PDA). Similar to DOPA, PDA can tightly adsorb on the surface of materials. Moreover, PDA 
is an excellent reducing agent that can be employed to produce metal nanoparticles via direct reduction of a 
metal precursor salt at room temperature [94-96]. 
 
 
Figure 12 Polydopamine synthesis occurs via two pathways: (A) a pathway of covalent bond-forming oxidative 
polymerization and (B) a newly proposed pathway of physicalself-assembly of dopamine and DHI [98]. 
 
Thanks to its chemical properties (reactivity with nucleophiles, its ability to chelate metal ions, and its redox 
activities) polydopamine can be applied to various types of surface with the aim of creating new materials 
with advanced properties. Polydopamine is spontaneously formed by pH-induced, oxidative polymerization 
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of dopamine-hydrochloride in alkaline solutions (pH > 7.5), but the molecular mechanism behind 
polydopamine formation is not fully clarified yet. It has been suggested that polydopamine formation shares 
many characteristics with melanin biosynthesis pathways [97]. Melanin biosynthesis includes an oxidative 
reaction pathway, which transforms dopamine into 5,6-dihydroxyindole (DHI), followed by further 
polymerization steps.  
Polydopamine is formed through two different pathways, non-covalent self-assembly and covalent 
polymerization where the first process occurs in parallel with the second one (Figure 12). Moreover, a 
significant amount of dopamine remains unpolymerized as a self assembled stable complex [98]. 
Thanks to its chemical structure, that incorporate many functional groups, polydopamine is not only used as 
a coating material but also for applications across the chemical, medical, biological and materials sciences 
(Figure 13). These functional groups (such as catechol, amine, and imine) can serve as starting points for 
covalent modification with a wide numbers of molecules or for the loading of metal ions.  
The primary advantage of polydopamine is that it can be easily deposited on all types of inorganic and 
organic substrates, with controllable film thickness and durable stability. In this way it is possible to create 
numerous multifunctional substrates with specific properties, using the grafting of diverse species including 
DNA [99], proteins [100], growth factors [101], hydroxyapatites [102], noble metal nanoparticles [103], 
polymers [104] and other molecules [105−107]. 
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Figure 13 (A) A brief timeline for the development of the use of polydopamine in different application. (B) The number of 
publications in terms of polydopamine sorted by year [108]. 
 
1.3.5 Polyethylenimine (PEI) 
The versatility of PEI is to be either a linear or a branched polymer, and its use is determined by these 
structural chain properties. Branched polyethyleneimine (B-PEI) contains branched chains of primary, 
secondary, and tertiary amino groups, in a 1:2:1 ratio, and has been produced since the early 1940s by acid-
catalyzed aziridine-based aqueous solutions [109]. 
Linear polyethyleneimine (L-PEI), also known as crystalline polyethyleneimine, is made of – (CH2–CH2–
NH)– repeating units and was first synthesized in 1970 by Dick by cationic polymerization of 2-substituted-
2-oxazolines [110]. 
PEIs have been extensively studied as a vehicle for DNA delivery system thanks to the electrostatic 
interactions between the positively charged polymer and the negatively charged phosphate groups of DNA. 
In aqueous solution, PEI condenses DNA and the resulting PEI/DNA complexes, carrying a net positive 
surface charge, can interact with the negatively charged cell membrane and be readily internalized into cells 
[111]. 
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1.3.6 Bisphosphonates 
 
Bisphosphonates (BPs) are currently the major class of drugs used for the treatments of osteoporosis and 
other diseases characterized by increased bone resorption, like Paget’s disease and bone-related cancers.  
The first examples of BPs were developed in the 1970s and 1980s for the treatment of diseases characterized 
by abnormal calcium metabolism but was only in the late 1990s, thanks to a successful screening of new 
compounds in short term rat models [112,113], that the importance of bone affinity and the involvement of 
cellular target of BPs were showed.   
BPs are synthetic pyrophosphate analogs, in which the P-O-P group is replaced by the P-C-P bridge, where 
the two P are two phosphonic acid groups bound to the same carbon (Figure 14). 
 
 
Figure 14 Structure of inorganic pyrophosphate and a generic bisphosphonate [114]. 
 
Stability is conferred by the carbon atom that connects the two phosphonates, making the molecule able to 
withstand incubation in acids or with hydrolytic enzymes.  
The P-C-P moiety is responsible for the strong affinity of the bisphosphonates for the skeleton and allows for 
a series of variation in the structure based on the substitution of the R1 and R2 sidechains. The ability of the 
BPs to bind to bone mineral is enhanced when the R1 sidechain is a hydroxyl group [115] because it 
increases the affinity for bone mineral, owing to the ability of these bisphosphonates to chelate calcium ions 
more  effectively by tridentate rather than bidentate binding.  
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In the years, several kinds of bisphosphonates with different groups in the R1 and R2 chains were studied, 
giving rise to different classes of molecules, with different properties (Figure 15). 
In particular, bisphosphonates containing a basic primary nitrogen atom in an alkyl chain (as pamidronate 
and alendronate) were found to be 10-100 fold more potent than the non-nitrogen containing molecules. In 
the nitrogen containing class, there are also ibandronate, olpadronate, risedronate and zoledronate. The two 
first molecules  contain a tertiary nitrogen that enhances the ability to inhibit bone resorption, and the last 
two types, containing a nitrogen atom within a heterocyclic ring, are 10.000 fold more potent than etidronate, 
in some experimental system [116].  
 
 
Figure 15 Structure of non-nitrogen containing bisphosphonate, alkyl-amino bisphosphonate and heterocyclic nitrogen 
containing bisphosphonate [120]. 
 
Altrough the structure of the R2 side chain is the major determinant of antiresorptive potency, both 
phosphonate groups are also required for the drugs to be pharmacologically active. Infact, alteration to one or 
both phosphonates groups reduces the affinity for bone mineral and consequently the activity [117]. 
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Some studies suggest that the ability of bisphosphonates to inhibit bone resorption is dependent on two 
separate properties of the BPs molecules [118]. The two phosphonate groups, together with a hydroxyl group 
at the R1 position, impart high affinity for bone mineral and act as a “bone hook”, allowing rapid and 
efficient targeting of bisphosphonate to bone mineral surfaces [116]. Once localized within bone, the 
structure and the three dimensional conformation of the R2 side chain determine the biological activity of the 
molecule and influence the ability of the drugs to interact with specific molecular target.  
The likelihood and the duration of the attachment of BPs to bone can be predicted considering the binding 
affinity of this molecules to HA, as demonstrated in some studies [119] which showed the following affinity 
rank order: clodronate < etidronate < risedronate < ibandronate <alendronate < pamidronate < zoledronate.  
The binding affinity and consequently the loading capacity can be also influenced by the physicochemical 
properties of N-BPs, such as molecular charge [110]. 
When BPs bind to HA, the nitrogen in the R2 side chain would be expected to confer a charge at the mineral 
surface, resulting in a differential change in zeta potential [121]. These changes might have multiple 
consequences, including effects on the further binding of charged molecules, the total amount of BP that can 
bind to the bone surface (loading capacity), cellular distribution, skeletal distribution, and interactions with 
charged ions and matrix constituents. 
 The more positively charged BPs (alendronate, ibandronate, and zoledronate) should create a more 
positively charged bone surface and thereby may attract additional BPs to bind to the bone surface via their 
negatively charged phosphonate moieties. This may further augment the accumulation of BPs and increase 
the maximum binding capacity on the bone crystals. 
On the other hand,  the less positively charged N-BPs (e.g., risedronate) lead to a more negatively charged 
bone surface, which may limit further accumulation of BPs, and therefore lessen the maximum binding 
capacity on the crystal surface. Thus, zeta potential may be an independent property that does not correlate 
directly with affinity, but rather influences binding capacity. 
Small changes in BP chemical structure have been shown to lead to substantial changes in the three 
dimensional (3-D) shape and atomic orientation. Therefore, it is postulated that the 3-D configuration of a 
nitrogen-containing BP (N-BP) and the orientation of its nitrogen may play an important role in mineral 
binding affinity [122-124]. 
36 
 
Some N-BPs can form N-H-O hydrogen bonds on the HA surface. These N-H-O hydrogen bonds can be 
formed at two sites on HA and require an N-H-O angle ≥125° and an N-O distance of approximately 3 Å for 
optimal binding. One H binding site can occur at a hydroxyl at the same position in which fluoride is known 
to substitute. This hydroxyl is coordinated to the second type of calcium (CaII) in HA.  
A second H bonding interaction can occur at neighboring calcium (CaI), which can optimally allow a 
bifurcated dual bonding arrangement. Overall, this indicates that N-BPs that can form any of these bonds 
will have a higher affinity for bone mineral [132].  
The clinical efficacy of BPs primarily stems from two key properties: their ability to bind strongly to bone 
mineral (they inhibit the de novo precipitation of calcium phosphate from solution, delay the transformation 
of amorphous to crystalline HA, and inhibit the aggregation and dissolution of HA crystals [125-127], and 
their inhibitory effect on mature osteoclasts.  
The adsorption of bisphosphonates to HA bone mineral surfaces brings them into close contact with 
osteoclasts and other cells in the bone.  
During the process of bone resorption, the subcellular space beneath the osteoclast is acidified by the action 
of vacuolar-type proton pumps in the ruffled border of the osteoclast membrane. The acidic pH of this 
microenvironment causes dissolution of the hydroxyapatite bone mineral, whilst the breakdown of the 
extracellular bone matrix is brought about by the action of proteolytic enzymes. Since bisphosphonates 
adsorb to bone mineral, especially at sites of bone resorption where the mineral is most exposed [128-130], 
osteoclasts are the cell type in bone most likely to be exposed to the highest concentrations of free, non-
mineral-bound bisphosphonate, as a result of the release of the bisphosphonate from bone mineral in the low 
pH environment beneath osteoclasts. 
At molecular level, Bisphosphonates act in two different ways (Figure 16). The simple BPs are metabolized 
to toxic analogues of ATP, it is likely that intracellular accumulation of these metabolites within the 
osteoclast inhibits osteoclast function and may cause cell apoptosis. 
In contrast, the nitrogen-containing bisphosphonates interfere with other metabolic reactions, for example, 
the mevalonate pathway [130-132] that is responsible for the production of cholesterol and isoprenoid lipids, 
such as isopentenyldiphosphate (IPP), farnesyldiphosphate (FPP), and geranylgeranyldiphosphate (GGPP). 
FPP and GGPP are responsible for the prenylation of small GTPases  (like Ras, Rho, Rac ) which are 
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important signaling proteins that regulate a variety of cell processes important for osteoclast function, 
including: cell morphology, cytoskeletal arrangement, ruffled border  and apoptosis [133, 134]. 
Prenylation is required for the correct function of these proteins, since the lipid prenyl group serves to anchor 
the proteins in cell membranes and may also participate in protein-protein interaction [135,136]. 
 
 
Figure 16 Mechanism of action of nitrogen containing bisphosphonate and simple bisphosphosphonate [120]. 
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1.4 Adsorption / Release 
Adsorption processes involve two substances. One is the solid or the liquid on which adsorption occurs and it 
is called adsorbent. The second is the adsorbate, which is the gas or liquid or the solute from a solution 
which gets adsorbed on the surface. 
Depending upon the nature of forces existing between adsorbate molecules and adsorbent, adsorption can be 
classified into two types: 
 
1. Physical adsorption (physisorption): If the force of attraction existing between adsorbate and adsorbent 
are Vander Waal’s forces, the adsorption is called physical adsorption. It is also known as Vander Waal’s 
adsorption. In physical adsorption the force of attraction between the adsorbate and adsorbent is very weak, 
therefore this type of adsorption can be easily reversed by heating or by decreasing the pressure. 
  
2. Chemical adsorption (chemisorption): If the force of attraction existing between adsorbate and 
adsorbent is almost of the same strength as chemical bonds, the adsorption is called chemical adsorption. It is 
also known as Langmuir adsorption. In chemisorption the force of attraction is very strong, therefore 
adsorption cannot be easily reversed.  
 
Isotherm adsorption models 
An isotherm is a model that describes the retention/release or mobility of a substance from the aqueous 
porous media or aquatic environments to a solid-phase at a constant temperature and pH [137]. 
Adsorption equilibrium (the ratio between the adsorbed amount and that remaining in the solution) is 
established when the adsorbate containing phase has been in contact with the adsorbent for sufficient time, 
and the adsorbate concentration in the bulk solution is in a dynamic balance with the interface concentration 
[138,139]. 
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The parameters obtained by the isotherm equation express the surface properties and the affinity of the 
adsorbent, at a fixed temperature and pH.  
To evaluate the accuracy of the fit of a two parameters isotherm model, the magnitude of the coefficient of 
determination (R
2
) for the linear regression has to be close to the unity. 
Over the years, a wide variety of equilibrium isotherm models have been formulated, those used for this 
study are described later. 
 
Langmuir Isotherm 
The Langmuir isotherm can be obtained based on the following key assumptions: 
• adsorption is localized and reversible; 
• adsorption sites are energetically equivalent, with no lateral interaction and steric hindrance between the 
adsorbed molecules, even on adjacent sites 
These assumptions imply that each site can adsorbs a maximum of one molecule of solute, and that the 
probability of adsorption is the same for each site. The formula of the isotherm is: 
 
 
 
where: 
N is the amount of BPs adsorbed at saturation, expressed in mg of adsorbed molecules / m
2 of solid or μmol/ 
m
2
 
K is the affinity Langmuir constant of adsorbed molecules for the slid expressed in mol/L  
K and N can be determined by plotting Ceq / Qads vs Ceq  . 
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Freundlich Isotherm 
The Freundlich isotherm describes the non-ideal and reversible adsorption, not restricted to the formation of 
a monolayer. This empirical model can be applied to multilayer adsorption, with non-uniform distribution of 
adsorption heat and affinities over the heterogeneous surface [140]. In this perspective, the amount adsorbed 
is the summation of adsorption on all sites (each having bond energy), with the stronger binding sites 
occupied first, until adsorption energy exponentially decreases upon the completion of adsorption process 
[141]. 
The formula of the isotherm is: 
 
 
K is a constant expressed in μmol/m2 and n express the surface heterogeneity. 
The slope ranges between 0 and 1 is a measure of adsorption intensity or surface heterogeneity, becoming 
more heterogeneous as its value gets closer to zero. On the other hand, a value below unity implies 
chemisorption process where 1/n above one is an indicative of cooperative adsorption [142]. 
Langmuir- Freundlich Isotherm or SIPS 
The Langmuir-Freundlich isotherm is commonly used to describe the adsorption characteristic for the 
heterogeneous adsorption systems  and with a low interaction Adsorbate/Surface. At low adsorbate 
concentrations, it reduces to Freundlich isotherm; while at high concentrations, it predicts a monolayer 
adsorption capacity characteristic of the Langmuir isotherm [143]. 
The formula of the isotherm is: 
 
 
 Where N (L/mM), K (µmol/m²), n express the surface heterogeneity and lateral interactions parameters. 
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1.4.2 Drug Delivery 
 
A way to treat bone disorders is by using local drug delivery devices. The local delivery of drugs should 
greatly reduce any systemic toxicities and side effects and open the door to entire classes of new treatments. 
These combined systems are able to administer high drug concentration in relevant tissues and to precisely 
control the timing of a drug release by adjusting the properties of the carriers.  
For this purpose, synthetic polymers are widely used [144] because they do not cause any considerable 
inflammation to tissues at the implantation site. In that case, the release of biomolecules can be regulated by 
various mechanisms: desorption, diffusion, carrier degradation, and environmental stimuli, or controlled by 
the combination of the abovementioned factors (Figure 17) [145]. 
 
 
Figure17 Schematic diagram of various mechanisms for biomolecules release from carrier devices. (A-D) and typical 
corresponding pharmacokinetics (a-d). (A) and (a) desorption controlled release; (B) and (b) diffusion controlled release; (C) 
and (c) degradation controlled model; (D) e (d) stimuli-triggered release [145]. 
 
Typical desorption-controlled delivery vehicles are carriers in which biomolecules cannot penetrate inside 
the carrier network. 
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However, limitations of this strategy are obvious, including the tendency of biomolecules to deactivate 
during adsorption, poor capacity of delivering hydrophilic molecules, and poor control over delivery, 
retention, orientation, or desorption rate of biomolecules [146]. 
Hydrogels and polymeric fibrous membranes, that allow diffusional loading of biomolecules into polymer 
networks, act as drug delivery systems through diffusion process and  provide a protective environment for 
biomolecules, prolonging their retention at treatment sites. The release profile for diffusion controlled 
delivery systems is normally characterized by an initial burst release, followed by a phase of sustained 
release that can be further regulated by fine-tuning the physicochemical properties of carrier materials [147]. 
Fragile biomolecules can be immobilized by physical or chemical interaction and thus be preserved from 
harsh environmental factors, and released with high degree of controllability by tailoring molecular weight, 
crosslinking and morphology of the carrier materials. In this case a degradation-controlled release system can 
occur. 
Finally, molecules can be released with “programmed” or “triggered”  systems working thank to 
environmental factors (e.g. pH, protein, glucose) or by external stimuli (e.g. temperature, ultrasound and 
irradiation) [148,149]. 
Although most of these drug carriers are polymers, some inorganic materials can also play a role. Indeed, 
calcium phosphate based materials, in various forms including ceramics, cements, composite and thin 
coatings, could have an added value as drug carriers for the bone tissue.  
From the biological point of view, CaPs can be resorbed by cells, present evident osteoconductive and 
bioactive properties.  Moreover, another relevant property of calcium phosphates is their unique ability to 
adsorb different chemical species on their surfaces. 
Since the 90s, a large number of works describing different types of calcium phosphate / biomolecules 
system are reported in the literature. The combination of therapeutic agents such as cisplatin with poorly or 
well crystallized calcium phosphate [150]; the combination of antibiotics such as gentamycin, vancomycin 
and ampicillin with calcium phosphate cements [151,152], the incorporation of growth factors in calcium 
phosphate apatites [153,154], are just few examples.  
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However, most of these studies focus on the study of the processes of association or incorporation and  the 
nature of the interactions molecules-media, and provide little or no details about the release mechanism 
involved in these associations. 
Among the therapeutic molecules mostly used for the treatment of bone diseases, there are various 
compounds of the BPs family.  In the case of BPs, a targeted and controlled release would notably increase 
the bioavailability of the active substance in the body and reduce the side effects [155,156]. 
Thus, alendronate, a BP molecule, has been associated with matrix-type systems such as hydrophilic matrix 
based polymer [157] or a mesoporous material ordered silica [158] to allow its local release. In the case of 
these two studies, the identified release mechanism is a BP diffusion through the matrix. 
In addition, the release of alendronate has been studied repeatedly [159] from polymer based composite 
microspheres (PLGA) and from nanocrystalline apatite [160]. 
 
1.5 Applications of CaPs as coatings of metallic implants 
 
Metals have been used in medical implants for many centuries because they provide the necessary strength 
and toughness that are required in load-bearing parts of the body. 
On the other hand, metallic implants show various side effects caused by their high potential to corrode and 
leak corrosion product in the biological environment, which generally causes inflammation and osteolysis. 
Additionally, their low surface hardness and high friction coefficient limit their biomedical applications. 
Another problem associated with metallic implants is that they are bioinert materials and consequently they 
are incapable of inducing osteogenesis. 
Improved implant fixation to hard tissues can be achieved by coating the metallic surface with a thin film of 
calcium phosphates. The deposition of calcium phosphates films on medical implants enable to combine the 
high mechanical strength of metallic implant with excellent bioactivity of the calcium phosphates surface 
layers. 
Coatings can be deposited by several physical and chemical methods, including plasma spray, pulsed laser 
deposition, sputtering, electrodeposition, anodic deposition and anodic spark deposition, sol-gel dipping and 
biomimetic deposition [161-175]. 
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Among these numerous techniques, pulsed laser deposition (PLD) is commonly used to produce calcium 
phosphate coatings, because this method is characterized by high deposition rate as well as possibility of 
precise control of thickness and composition of the growing layer (Figure 18). 
On the other hand, PLD applied to organic and polymeric materials tends to cause some degree of 
irreversible decomposition or damage because the interaction of the UV photons with the polymeric or 
organic molecules causes the loss or decomposition of functional groups. 
 
 
Figure 18 Scheme of the PLD technique (www.andor.com) 
 
One approach that has shown great promise, in the case of polymeric or organic molecules, is known as 
matrix-assisted pulsed laser evaporation, or MAPLE. 
 
Matrix-Assisted Pulsed Laser Evaporation 
The MAPLE process was developed in the late 1990s at the U.S. Naval Research Laboratory to provide a 
gentler pulsed laser evaporation process for functionalized polymers [176]. 
In MAPLE deposition technique, the pulsed laser beam is focused on a target obtained as a frozen solution in 
a relatively volatile solvent of the molecules to be deposited (Figure 19). The advantage of MAPLE with 
respect to PLD technique is that a great part of the laser beam energy is transferred to the solvent and 
molecules to be deposited, which are ejected from the target mainly due to solvent vaporization. 
In MAPLE, the target usually contains 55 wt% of solute material, that is, polymer or biomaterial to be 
deposited. Thus, each polymer or biomaterial molecule is surrounded or shielded by a large amount of 
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solvent or matrix, reducing both thermal and photonic damage to the polymer or biomaterial in solution, 
during their laser-induced volatilization. Ideally, the solute molecules are entrained in the plume of matrix 
molecules leaving the frozen target due to collisions between the matrix and the embedded polymer or 
biomaterial molecules. 
The substrates are typically at room temperature during the MAPLE deposition process, but they can be 
heated slightly to anneal the growing film. Typically, an excimer laser is used (KrF at 248 nm or ArF at 193 
nm) with 10- to 30-ns pulse width, at repetition rates between 1 and 20 Hz, focused to a 1 to 10 mm
2
 spot 
size on the target, although other types of lasers with wavelengths ranging from the visible to the infrared 
(IR) can be employed as well. The laser fluence at the target is typically set between 0.01 and 0.5 J/cm
2
, 
depending on the solute material and solvent used. The depositions can be carried out at pressures ranging 
from vacuum to a few hundred millitorr and in the presence of inert or reactive background gases, in the 
same manner as conventional PLD. 
The matrix solution is prepared by dissolving the organic or polymeric material in a solvent such as water, 
various types of alcohols, acetone, toluene, and so forth. To make a target, a few milliliters of the solution 
are flash frozen in a target die by submerging it in liquid nitrogen (LN2). Once frozen, the MAPLE target is 
mounted on a cryogenically cooled rotating target holder with the open die and facing the laser. When a 
substrate is positioned directly in the path of the plume, a coating starts to deposit from the evaporated solute 
molecules, while the volatile solvent molecules, which have very low sticking coefficients, are evacuated by 
the pump in the deposition chamber. 
One advantage of the MAPLE process is that it can easily be combined with noncontact shadow masks to 
limit the deposition to only those required areas on a substrate. 
This is important for fragile substrates and is much less time-consuming than subsequent removal by 
patterning and etching.  
Despite the great success achieved with the MAPLE technique for the deposition of polymers and 
biomaterials, this process is not without certain important drawbacks. First, the typical deposition rates that 
can be achieved with MAPLE are about an order of magnitude lower than those for conventional PLD. 
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Furthermore, the solvent molecules might be subject to photochemical reactions during their interaction with 
the laser pulse, which in some cases can result in the generation of highly reactive radicals that can alter the 
chemical structure and functionality of the solute polymer or biomaterial being deposited. 
Another aspect that must be taken into consideration when using MAPLE is the resulting film surface 
morphology because, more often than not the surface morphology of the films tends to be rough and in some 
cases large droplets are present as well. 
The film roughness not only depends on processing conditions but also on the type of polymer or organic 
being deposited and in the case of many biomaterials might not be modifiable due to the characteristic 
intrinsic arrangements of the molecular chains. For some applications, such as in biosensors, higher surface 
areas resulting from the rough film morphology might be desirable since they increase the area for analyte 
binding. 
 
 
Figure 19 Schematic of the MAPLE technique: the vacuum chamber and detail of the target [177]. 
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2. Aim of the research 
 
This PhD thesis is aimed to develop new materials based on calcium phosphates functionalized with ions and 
molecules with anti-resorptive, anti-inflammatory and/or anti-bacteric properties for the local treatment of 
bone defects caused by injuries or pathologies.  
Bone metabolism diseases are generated when there is an imbalance between the formation of new bone 
tissue and its resorption process. In turn, these two mechanisms depend on the interaction between 
osteoblast, cells responsible for the new bone formation, and osteoclast, which are responsible for the bone 
resorption. Calcium phosphates are excellent candidates for the preparation of biomaterials capable of 
supporting bone cell proliferation and promote osteogenic activity, and therefore the regeneration of bone 
tissue. Furthermore, such materials are susceptible to osteoclastic degradation, which promotes their 
complete replacement with new functional bone. The continuous aging of the population has led to a serious 
rise in the demand of orthopaedic implants, and in particular of materials able to couple the excellent 
biocompatibility and bioactivity of calcium phosphates with the therapeutic properties of functionalizing 
agents. Moreover, an ideal implant should be able to avoid bacterial colonization, which causes asepting 
loosening and infections and provokes implant failure. 
On this basis, the program involves the following research lines: 
 
a) functionalization of calcium phosphates with bisphosphonates 
 
Bisphosphonates (BPs) are currently the major class of drugs used for the treatment of osteoporosis and other 
metabolic bone diseases such as Paget's disease, osteogenesis imperfecta and bone metastases [120,178]. 
However, their prolonged systemic administration has several side effects, including osteonecrosis of the jaw 
and atypical subtrochanteric fractures [179, 180]. Local administration at specific bone sites has been 
proposed as an alternative strategy to deliver N-BPs and avoid/reduce the potentially side-effects of their 
prolonged systemic use. 
One of the objectives of this thesis is to study the role of composition and surface charge of hydroxyapatite 
on the adsorption and release mechanisms of risedronate.  To this aim, different apatitic substrates, namely 
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HA with a partial substitution of zinc to calcium (ZnHA), HA and ZnHA functionalized with 
polyethyleneimine (HAPEI, ZnHAPEI), as well as HA as control material, have been submitted to 
interaction with risedronate. The investigation includes the study of the adsorption isotherms of the 
bisphosphonate on the different substrates, the physicochemical characterization of the products, the analysis 
of the process of drug release. 
Functionalization of octacalcium phosphate with alendronate and zoledronate was performed through direct 
synthesis in aqueous solution in the presence of increasing concentration of the BPs. The results of the 
physicochemical characterization of the products allow to get useful information on the structural interaction 
between the calcium phosphate and the functionalizing molecules. 
Moreover, a series of samples containing different amounts of calcium alendronate monohydrated and 
octacalcium phosphate have been utilized to verify the possibility to deposit thin films of the composite 
materials using Maple Assisted Pulsed Laser Evaporation, with the aim to realize coatings with anti-
osteoporotic properties. 
 
b) functionalization of calcium phosphates with quercetin 
 
 Flavonoids, which are widely spread in vegetables and fruits, find useful applications as anti-
oxidant, anti-bacterial, anti-inflammatory and anti-viral agents [181]. In particular, quercetin has 
also been suggested to inhibit bone resorption in vitro and to exhibit chemo-preventive and/or 
chemotherapeutic properties [83, 182]. 
The interaction of quercetin with hydroxyapatite was investigated through different methods of synthesis, 
and through adsorption from solution. Moreover, the possibility to adsorb quercetin on alendronate 
functionalized hydroxyapatite was also investigated. The study was extended to a high soluble calcium 
phosphate, monetite, as well as to monetite with a partial substitution of strontium to calcium, both of which 
were proven to be able to adsorb the flavonoid. All the products were submitted to chemical, morphological 
and structural characterizations. In particular, the anti-oxidant properties of the different materials were 
investigated through evaluation of their radical scavenging activity. 
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c) calcium phosphates enriched with Ag Nanoparticles 
 
In order to create materials with antimicrobial properties, octacalcium phosphate and α-tricalcium phosphate 
were used as supports for silver nanoparticles. In fact, silver ions and silver-based compounds are highly 
toxic to microorganisms which include 16 major species of bacteria [183, 184]. Deposition of Ag 
nanoparticles on the surfaces of the calcium phosphates was performed using polydopamine as 
functionalizing and reducing agents. The products were characterized using powder X-ray diffraction 
technique, scanning electron microscopy, ICP and thermogravimetric analyses.  
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3. Materials   
 
3.1 Syntheses  
 
3.1.1 Hydroxyapatite  
 
The synthesis of HA was carried out in N2 atmosphere using CO2 free water. 50 ml of a 1.08 M 
Ca(NO3)24H2O solution (pH adjusted to 10 with NH4OH) was heated at 90°C and 50 ml of 0.65 M 
(NH4)2HPO4 solution was added drop-wise under stirring. The precipitate was maintained in contact with the 
reaction solution for 5 h at 90 °C under stirring, then centrifuged at 10,000 rpm for 10 min and repeatedly 
washed with CO2-free distilled water. The product was dried at 37°C overnight [185].  
 
3.1.1.1 Hydroxyapatite - Quercetin 
 
The synthesis of HA in the presence of quercetin was carried out in a solution of ethanol and CO2-free 
deionized water in an inert atmosphere (N2) following two different procedures: (a) direct synthesis of HA 
and (b) phase transition from DCPA, a more soluble phase, that easily hydrolyzes into HA. The direct 
synthesis was performed through a modification of a classical method. In particular, the synthesis was 
carried out in the presence of different amounts of quercetin dihydrate (Sigma; water solubility < 4%) added 
into the Ca(NO3)24H2O solution hydro alcoholic (1/1 V/V) , namely 85 mg, 170 mg and 255 mg, which 
correspond to a final concentration of 2.8 mM, 5.6 mM and 8.4 mM respectively. The resulting solid samples 
were labeled as D0, D85, D170, and D255, where digits indicate the quantity (mg) of quercetin powder used 
in the specific preparation.  
For the synthesis of monetite, 50 mL of a 0.65 M (NH4)2HPO4 aqueous solution was added drop-wise to 50 
mL of a 1.08 M Ca (NO3)2 * 4H2O hydro alcoholic (1/1 V/V) solution maintained at 65°C. The pH of both 
solutions was not modified, keeping the spontaneous pH (about 5). After 6 days storage in solution, the 
precipitate was separated, washed and dried as reported above for the direct synthesis of HA. The same 
synthesis procedure was carried out in the presence of different amounts of quercetin dehydrate (Sigma) 
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added into the Ca(NO3)24H2O solution, namely 85 mg, 170 mg and 255 mg. The corresponding samples 
were labeled as MON0, MON85, MON170, and MON255. Phase transition from monetite to HA was 
obtained by a modification of the last part of the procedure followed for the synthesis of monetite: after 
keeping the precipitates in contact with the solution at 65°C under stirring for 6 days, the pH of the reaction 
mixture was adjusted to 9 with ammonia solution 25% and the temperature raised to 90°C. After 5 h under 
stirring, the reaction products were centrifuged at 10,000 rpm for ten minutes and repeatedly washed with 
CO2-free deionized water. The solid samples were dried at 37°C and labeled as T0, T85, T170, and T255, 
where digits indicate the quantity of quercetin powder used in the specific preparation [93]. 
 
3.1.1.2 Hydroxyapatite - Poly(etyhlenimine)  
 
Hydroxyapatite at different poly(ethylenimine) contents was obtained by adding PEI to the Ca(NO3)24H2O 
solution, before adjusting the pH to 10 with NH4OH. Poly(ethylenimine) solution (Aldrich, MW~2000) was 
used. Concentrations of PEI were 1, 2 and 4 M calculated on the final volume, the obtained samples were 
labeled as HAPEI 1, HAPEI 2 and HAPEI 4.  [186] 
 
3.1.1.3 Hydroxyapatite – Alendronate 
 
Following the standard synthesis of hydroxyapatite, after the addition of 25 ml of phosphate solution, 25 ml 
of alendronate solution 14mM (calculated on final volume) were dropped under stirring in the reaction 
vessel. The precipitate was maintained in contact with the reaction solution for 5 h at 90°C under stirring, 
then centrifuged at 10,000 rpm for 10 min and repeatedly washed with CO2-free distilled water. The product 
was dried at 37°C overnight [187], named HAAL. 
 
3.1.1.4 Zinc – Hydroxyapatite (ZnHA) 
 
Zn substituted hydroxyapatite was synthesized following the hydroxyapatite experimental procedure, but the 
cationic solution was prepared by dissolving the appropriate amounts of Ca(NO3)24H2O and 
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Zn(NO3)26H2O in CO2-free deionized water before adjusting the pH to 10 with NH4OH. The total cationic 
concentration was 1.08 M, and the Zn/(Ca + Zn) molar ratio was 0.1 [60]. 
 
 
3.1.2 Octacalcium Phosphate  
 
The synthesis of OCP was carried out by dropwise addition of 250 ml of 0.04 M Ca(CH3COO)2 (over a period 
of 50 min) into 750 ml of a phosphate solution containing 5 mmol of Na2HPO4 and 5 mmol of NaH2PO4 at 
starting pH 5. The reaction was carried out at 70°C under mechanical stirring. After 30 min the precipitate was 
filtered, repeatedly washed with distilled water and dried at 37°C [188]. 
 
3.1.2.1 Alendronate/Zoledronate - Octacalcium Phosphate 
 
Similarly, the synthesis of OCP in the presence of Zoledronate was carried out by dropwise addition of 250 ml 
Ca(CH3COO)2 solution into 700 ml of a phosphate solution containing 5 mmol of Na2HPO4 and 5 mmol of 
NaH2PO4 at starting pH 5; afterwards the resulting slurry was stored under stirring for 30 min and then 50 ml 
of the bisphosphonate solution was added dropwise over a period of 10 min. Immediately after the addition of 
Zoledronate, the precipitate was filtered, repeatedly washed with distilled water and dried at 37°C. 
Zoledronate concentration was in the range 0.1 – 1.5 mM, calculated on the final volume.   
The synthesis of OCP in the presence of Alendronate was performed in the same condition of the modified 
synthesis of OCP-Zoledronate. Alendronate concentration was in the range 0.1 - 1.5 mM, calculated on the 
final volume [189]. 
Samples were labeled as OALXX,in the case of Alendronate, or OZOLXX, in the case of Zoledronate, 
where XX indicates the concentration of BP in solution (expressed as mM). 
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3.1.3 -TriCalcium Phosphate 
 
α-TCP was obtained by solid-state reaction of a mixture of CaCO3 and CaHPO4 · 2H2O in the molar ratio of 
1:2 at 1300°C for 5 hours [190]. 
 
3.1.4 DiCalcium Phosphate Anydrous  
 
The synthesis of monetite was carried out using 50 ml of a 1.08 M Ca(NO3)24H2O solution heated at 90°C 
and 50 ml of 0.65 M (NH4)2HPO4 solution that was added drop-wise under stirring. The precipitate was 
maintained in contact with the reaction solution for 5 h at 90 °C under stirring, then centrifuged at 10,000 
rpm for 10 min and repeatedly washed with distilled water. The product was dried at 37°C overnight [93]. 
 
3.1.4.1 DiCalcium Phosphate Anydrous  substituted with Strontium (SrDCPA) 
 
Sr substituted monetite was synthesized following the experimental procedure used for the synthesis of 
monetite, but including Sr ion in the cationic solution, which was prepared by dissolving the appropriate 
amounts of Ca(NO3)24H2O and Sr(NO3)25H2O in CO2-free deionized water before adjusting the pH to 10 
with NH4OH. The total cationic concentration was 1.08 M, and the Sr/(Ca + Sr) molar ratio was 0.2.  
 
 
3.2 Adsorption 
3.2.1 ZnHA – Polyethylenimime 
Absorption of PEI on pre-formed hydroxyapatite substituted with zinc at 10% (ZnHA10) was performed by 
soaking ZnHA10 powder (100mg) in an aqueous solution of 4 M PEI, under stirring for 24 hours. Then, the 
solid was centrifuged at 10,000 rpm for ten minutes and washed with deionized water. Finally, the powder 
was dried at 37 ° C and the sample was labeled as ZnHAPEI.  
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 3.2.2  Risedronate adsorption on different substrates 
Adsorption experiments were carried out at physiological temperature (37 ± 1° C), by dispersing 50 mg of 
powder (HA / HAPEI / ZnHA / ZnHAPEI) in 5 mL of risedronate solutions (concentration ranging from 0 to 
3 mM) in a polyethylene tube. The latter were prepared by dissolving the appropriate amount of risedronate 
in an aqueous 1 mM KCl solution (standard solution); the pH of the obtained solutions was adjusted to 7.4 
using hydrochloric acid and potassium hydroxide solutions. After sonication for 1 min, the suspensions were 
incubated for 1 h without stirring and centrifuged for 10 min at 5000 rpm. This equilibration time was 
previously determined from kinetic experiments using risedronate concentrations of 0.86 mM.  Blanks 
containing only the apatitic powders, prepared and incubated in the KCl solutions, were used as controls. 
After centrifugation, the solid products were washed with deionised water and dried at 37°C overnight. The 
supernatants were filtrated on 0.2 µm Millipore filters. The samples obtained by using the following supports 
HA,HAPEI, ZnHA, ZnHAPEI after risedronate adsorption were labeled, respectively, as HABP, HAPEIBP, 
ZnHABP and ZnHAPEIBP.  [186] 
 
 3.2.3 Calcium Phosphate – Quercetin  
Adsorption of quercetin on pre-formed HA, HAAL, DCPA and SrDCPA were carried out by soaking 500 
mg of powders in 20 ml of 6 mM hydroalcolic solution of quercetin (H2O/EtOH in the ratio 50/50), under 
stirring for 24, 48 and 72 hours at 37°. Then the solid products were filtered and washed with deionized 
water and dried at 37° overnight. The obtained samples were labeled HA24Q, HA48Q and HA72Q. The 
same format was used also for the other supports. 
 
3.2.4 Calcium phosphates-Silver Nanoparticles (AgNPs) 
Silver nanoparticles were loaded on octacalcium phosphate and on -tricalcium phosphate previously 
functionalized with a coating of polydopamine.  
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The final materials were obtained in two steps of functionalization. In the first one, the powders were put in 
contact in a 2mg/ml solution of TRIS buffer and dopamine hydrochloride at pH 8.5, under stirring. After 2 
hours the solution was filtered and the obtained solid repeatedly washed with distilled water and dried at 
37°C overnight. The obtained samples were labeled as OCPd and -TCPd. 
In the second step, 20ml of AgNO3 solution, at different concentration (1mM, 5mM and 10mM), and 20ml 
of sodium citrate solution 13mM, at room temperature under stirring, were added simultaneously to a becker 
containing the powders functionalised with dopamine. After one hour the solid was filtered repeatedly 
washed with distilled water and dried at 37°C overnight. The final products were named OCPd Ag1, OCPd 
Ag5, OCPd Ag10 and -TCPd Ag1, -TCPd Ag5, -TCPd Ag10.  
 
3.3 Release Tests 
3.3.1 BPs release from OCPZOL and OCPAL 
Bisphosphonate release tests were performed on disk-shaped samples (Ø= 6.0 mm). Each disk was prepared 
by pressing 60 mg of powder into cylindrical moulds by using a standard evacuable pellet die (Hellma).  
The obtained disks were immersed in 2 mL of 0.1 M Phosphate Buffer Solution (PBS) at pH of 7.4 for 
increasing time from 2 hours up to 7 days. The content of bisphosphonate was measured 
spectrophotometrically on the solid residue via complex formation with Fe(III) ions [191] using a Varian 
Cary50Bio instrument ( λ= 290 nm). 
 
3.3.2 Risedronate release from apatitic samples 
Risedronate release profiles were obtained with a flow through cells system with 12 mm cells (6 mL) and 
peristaltic pump. In all experiments, laminar flow was used with one glass beads layer covered with 
each BP-functionalized apatitic sample, mixed with 2 g of glass beads. Different weights were 
utilized for the analysis of the different materials so that all the samples contained the same amount 
of adsorbed BP (about 1.8 µmol/m
2
). The release tests were carried out at 37.0 ± 0.5 °C under sink 
conditions according to European Pharmacopoeia guidelines. The dissolution medium was deionized water 
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pumped through the column at a flow rate of 9 ml/min. A closed system was used, recycling 50 ml of 
dissolution medium. Periodically, fractions of 5 ml were collected and risedronate content was determined 
by UV spectroscopy at 262 nm. The same volume of dissolution medium was replaced back after each 
sampling in order to maintain constant volume and sink conditions. Each release analysis was performed in 
triplicate. 
 
3.4 Thin Film deposition OctaCalcium Phosphate- Alendronate 
Disk-shaped Ti substrates (12 mm diameter and 0.5 mm thick) were mechanically polished and submitted to 
chemical etching before being used as collectors. They were clean in ultrasonic sequential baths of acetone, 
alcohol and deionized water. For the preparation of one target used in MAPLE experiments, deionized H2O 
based solution containing 0.12 g of OCP powder was suspended in 10 ml and subsequently stirred, 
homogenized and frozen in a special cop-per holder at 77 K in liquid nitrogen. The holder containing the 
solid target was then mounted inside a vacuum chamber. During exposure to multipulse laser irradiation, the 
target was maintained frozen by continuous liquid nitrogen flow inside a supporting cooler device and 
continuously rotated with 80 rpm to avoid drilling and improve the overall quality of the deposited films. A 
pulsed KrF* laser source( λ= 248 nm, _FWHM≤ 25 ns) operating at 5 Hz was employed for their radiation 
of the target. 20,000 subsequent pulses were applied at an incident laser fluence of 0.73 J cm
−2
 for the 
synthesis of each assembly (the corresponding pulse energy was of 280 mJ). The deposition was carried out 
in a residual pressure of 13 Pa. The substrate was facing the target at a separation distance of about 4 cm, 
while its temperature was kept constant at 30◦C during deposition. Identical MAPLE conditions were applied 
for the deposition of AL8 andAL20 powders. The deposited coatings were labeled cOCP, cAL8, and cAL20 
[189]. 
AL8 andAL20 were prepared as follows: reaction of OCP and AL was carried out in bidistilled water in the 
presence of two different concentrations of sodium alendronate trihydrate (Chemos), that is 8 and 20 mM. 
Resulting solid samples have been labeled AL8 and AL20, respectively. The reaction was performed on 500 
mg OCP/250 ml solution at 30◦C, maintained under stirring for 72 h. Then the products were centrifuged at 
5000 rpm for 10 min, repeatedly washed with double distilled water and dried at 37◦C [189]. 
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4. Methods  
 
4.1 X-Ray Diffraction  
 
X-ray diffraction analysis was carried out by means of a PANalytical X’Pert PRO powder diffractometer 
equipped with a fast X’Celerator detector (40 mA, 40 kV). For phase identification the 2θ range was 
investigated from 3 to 60 2θ degrees with a step size of 0.1 and time/step of 100 s. To evaluate the coherence 
lengths of the crystals, further X-ray powder data were collected in the relevant regions of 2θ by means of 
step scans with a fixed counting time of 100 s for each 0.033/step. Data used for cell parameters calculations 
were collected from 10 to 60 2θ degrees counting for 400 s at each 0.033 (2θ) and processed with the 
Rietveld refinement analysis.  
For analysis of thin films deposited by means of MAPLE, the explored 2 θ° range was from 3 to 12°(2 θ 
)with a step size of 0.05° and time/step of 3000 s. 
 
4.1.1 Scherrer analysis  
 
For hydroxyapatite samples, the line broadening of the 002 and 310 reflections was used to evaluate the 
length of the coherent domains (hkl) along the c-axis and along a direction perpendicular to it.  
For octacalcium phosphate samples, a qualitative estimation of the size of the coherently scattering domains 
was performed from the line broadening of the (100), (002) and (010) reflections. τh k l values were calculated 
from the widths at half maximum intensity (1/2) using the Scherrer equation [192] 
 
 
τhkl= 
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where λ is the wavelength, θ the diffraction angle and K a constant depending on crystal habit (chosen as 
0.9). The silicon standard peak 111 was used to evaluate the instrumental broadening. 
 4.1.2 Rietveld refinement analysis 
In the Rietveld refimement the experimental pattern is calculated through a mathematical function, since the 
relation between the atom position and the intensity at each point of the powder profile are known. The pattern 
is reproduced by assuming it to be a sum of a number of well shaped Bragg reflections centered in their 
respective Bragg angle positions. A structural model is necessary in order to calculate the corresponding 
intensity at each yi calc step of the pattern, according to the equation (I): 
        ( )    ∑      [   ] 
  
 
(       )           
 
 (I) 
 
Where s is the scale factor, m is multiplicity factor, L is the Lorenz-polarization factor for the k reflection, F 
is the structure factor, G the reflection profile function, 2θ k is the calculated position of the Bragg peak, P is 
the preferred orientation factor, A is the adsorption factor, yib is the background value at point i. 
The purpose of this procedure is to find the best possible agreement between the observed pattern and a 
calculated profile. In order to get this goal the residual S: 
   ∑   [(              )]
 
 
 (II) 
Where wi= 1/yiobs, yiobs is the observed intensity at the i-th step and yi calc is the calculated intensity at i-th 
step. 
 
During this procedure two sets of parameters are varied: 
-non structural parameters, generally refined at the beginning of the procedure (scale factor, zero shift, 
background parameters, profile shape, asymmetry). 
-structural parameters, refined in the last steps of the procedure (unit cell parameters, atom position, 
occupation factor) 
This order could however change in according with the observed results on the calculated pattern after each 
step. 
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4.2 Fourier Transform Infra-Red and Raman Spectroscopy  
 
For the IR analysis, 1 mg of the samples were carefully mixed with KBr (250 mg, infrared grade) and 
pelletized under a pressure of 10 tons for 40 seconds. The pellets were analyzed using a Nicolet 380 FTIR 
spectrophotometer to collect 64 scans in the range 4000 – 400 cm-1 at a resolution of 4 cm-1. 
Raman spectra of the samples were generated on a Horiba, Jobin-Yvon Labram HR800 confocal 
microspectrometer, equipped with a helium–neon LASER (λ = 632.82 nm). The spectral resolution was 2 
cm
-1
 , the laser power was 2 mW and integration times varied from 30 to 120 s. All spectra were recorded 
over a wavelength range of 200–1800 cm-1. Three spectral accumulations were averaged. 
 
4.3 Inductively Coupled Plasma  
 
The quantification of Ag was performed using a quadrupole mass spectrometer with plasma source ICP MS 
XSeries Thermo Fisher Scientific. The samples were prepared by dissolving 10 mg of powders in water/ 
methanol solution 1/1 V/V. 5 ml were taken and added in 50 ml of 5% nitric acid solution.   
 
4.4 Microscopy 
 
Most morphological investigation was performed by scanning electron microscopy (SEM) using a Philips 
XL20 instrument operating at 15 kV. The samples were sputter-coated with Au before analyses. OCP 
functionalized with bisphosphonates were examined using a Phenom ProX desktop-scanning electron 
microscope at beam acceleration voltage of 10 kV. In this case the samples were observed as prepared and 
not sputter coated before examination. The ImageJ® picture analyzer software was used to estimate the mean 
crystals dimensions, averaging the measurements over at least 100 data points per sample.  
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For TEM investigations, a drop of sonicated powder suspension in ethanol was transferred onto holey carbon 
foils supported on conventional copper microgrids. A Philips CM100 transmission electron microscope, 
operating at 80 kV was used. 
For AFM imaging a Veeco Nanoscope 3D instrument was used. The samples were analyzed in tapping mode 
using a E scanner (- maximum scan size 15 μm) and phosphorus (n) doped silicon probes (spring constant 
20–80 N/m; resonance frequency 250– 290 kHz; nominal tip radius < 10 nm). Roughness parameters, 
namely arithmetic mean roughness (Ra), root-square roughness (Rq), and the vertical distance between the 
highest and lowest points within the evaluation length (Rt), were recorded. 
 
4.5 Surface Area Analysis by Gas Adsorption 
 
The specific surface area was measured using a Carlo Erba Sorpty 1750 BET analyzer using constant volume 
N2 absorption with desorption at 80 °C. 
 
4.6 Uv-Vis Spectroscopy   
 
Bisphosphonate content was determined spectrophotometrically via complex formation with Fe(III) ions 
using a Varian Cary50Bio instrument ( λ= 290 nm). 
Quercetin content was determined spectrophotometrically using a Varian Cary50Bio instrument (λ=256 and 
373 nm)  
 
4.7 Zeta Potential Measurement 
 
Zeta potential was measured using a Malvern Instruments Zetasizer Nano. 5 mg of powder sample was 
suspended in 50 mL of MilliQ water after sonication for 2 minutes. Each analysis was performed in 
triplicate. 
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4.8 Static Contact Angle Measurement 
 
Static contact angle measurements were performed on disk shaped samples (Ø = 13.0 mm). Each disk was 
prepared by pressing 100 mg of powder into cylindrical molds by using a standard evacuable pellet die 
(Hellma). A KSV CAM101 instrument was used under ambient conditions by recording the side profiles of 
deionized water drops for image analysis. The shape of the drop was recorded in a time range of 0–60 s, by 
collecting an image every 0.033 s. At least six drops were observed for each sample. 
 
4.9 Thermogravimetric Analysis 
 
Thermogravimetric analysis was carried out using a Perkin- Elmer TGA-7. Heating was performed in a 
platinum crucible in air flow (20 cm
3
/min) at a rate of 10 °C/min up to 900 °C. The samples weights were in 
the range 5–10 mg. Results from this analysis represent the mean value of determinations for three different 
samples of each composition. 
 
4.10 Radical Scavenging Activity 
 
Antioxidant activity was determined based on the Quercetin ability to act as radical scavengers toward the 
stable 2,2-diphenyl- 1-picrylhydrazyl free radical (DPPH˙). This method previously described by Gulcin 
[193] was used with slight modifications. Briefly, 50 µL of QUE and obtained samples in the concentration 
range 10.0–100.0 µM were added to 3 mL of DPPH˙ saturated ethanol/water (20/80 V/V) solution. Samples 
were kept under magnetic stirring for 10 min at RT in darkness to reach the steady-state condition; after 
samples centrifuging, absorbance readings were taken at 515 nm. The radical scavenging activity (RSA) was 
determined through the following equation: 
 
% RSA= (A0 – Ax)/A0 * 100 
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whereby A0 is the absorbance of the control (containing DPPH˙ solution without quercetin), and Ax is the 
absorbance in the presence of QUE or of obtained samples. 
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5. Results and Discussion 
 
5.1 Study of the antioxidant and bone repair properties of quercetin functionalized - 
hydroxyapatite   
Functionalization of hydroxyapatite with quercetin was carried out in order to get new materials for bone 
repair through local administration of the flavonoid [93]. Quercetin is a powerful antioxidant and anti-
inflammatory flavonoid with the capability to prevent bone loss.  
HA was synthesized in presence of different concentrations of quercetin according to two different 
procedures: direct synthesis and phase transition from monetite. 
The details of the procedures utilized to prepare the two sets of samples illustrated in the scheme in Figure 20 
are reported in chapter Materials, paragraph 3.1.1.1. 
 
 
 
   
 
 
 
 
 
 
 
 
5.1.1 Composite crystals obtained by direct synthesis 
The relative amount of quercetin in the different samples has been evaluated by thermogravimetric analysis 
(Figure 21). The results show an increase of quercetin content as the flavonoid concentration in the synthesis 
solution increases, up to a maximum value of 3.1 wt% (Table 3).  
Calcium + Quercetin  
pH 9 
Phosphate Solution 
D Samples 
Calcium + Quercetin  
Spontaneous pH  
Phosphate Solution 
NH3 
addition to 
pH 9 
T Samples 
5 hours 
a) 
b) 
Figure 20 Scheme of the synthesis procedures: a) direct synthesis of HA b) synthesis of monetite, followed 
by conversion to HA. 
T = 65°C 
6 days 
T = 90°C 
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The powder XRD patterns of all the samples obtained by direct synthesis show a number of diffraction peaks 
characteristic of the HA, which is present as unique crystalline phase (Figure 22). The broadening of the 
diffraction reflections grows with quercetin content, suggesting a reduction of crystallinity with composition. 
To better evaluate the contribution of this modification in the peaks shape, the length of coherently scattering 
domains (τhkl) has been calculated using the Sherrer equation and considering a negligible microstrain. In 
particular, it has been evaluated τ002, which is related to the mean crystallite size along the c-axis, and τ310, 
which refers to the mean crystallite size along a direction perpendicular to c-axis. The decrease of the mean 
crystallite size, along both crystallographic directions, with the increasing of quercetin content indicates that 
the presence of the flavonoid in solution inhibits the crystallization of HA.  
 
 
Table 3 Coherent lengths (τhkl) of the perfect crystalline domains in the direction normal to (002) and to (310) planes 
calculated using the Scherrer method; lattice parameters calculated using Rietveld method, Specific Surfaces Area, amount 
of quercetin associated to HA [93] 
Samples τ002 (Å) τ310 (Å) a (Å) b (Å) SSA (m
2
/g) Que (wt%) 
D0 471(1) 222(1) 9.428(2) 6.880(2) 66(7) - 
D85 429(3) 200(1) 9.436(4) 6.880(2) 70(7) 1.0(3) 
D170 387(1) 162(1) 9.435(1) 6.881(2) 92(9) 2.4(5) 
D255 357(1) 96(1) 9.436(2) 6.877(3) 120(11) 3.1(5) 
 
 
 
 
 
 
Figure 21 Thermogravimetric plots of the products obtained by (a) direct synthesis, and (b) phase transition [93]. 
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Figure 22 Powder XRD patterns of the products obtained by direct synthesis of HA in presence of different amounts of 
quercetin [93] 
 
TEM images (Figure 23) show that the crystals of sample D0 (HA reference) are characterized by a plate like 
morphology with well defined edges, elongated along one preferential direction that corresponds to the 
crystallographic c axis. The mean dimensions are about 40 x 20 nm. With the presence of quercetin, the 
crystals become smaller and thinner, and display more homogeneous dimensions. The presence of quercetin, 
instead, does not change significantly the morphology of the crystals.   
Coherently with the decrease of crystal dimensions, the surfaces area increases from 66 m
2
/g to 120 m
2
/g on 
passing from sample D0 to D255 (Table 3). 
 
 
Figure 23 TEM images of the products obtained by direct synthesis (D0, D85 and D255) scale bars = 200 nm [93]. 
 
The presence in the composite nanocrystals of a hydrophobic molecule, such as quercetin, does not affect the 
hydrophilic behavior of HA, as supported by the values of the contact angle: the angle of the water droplet, 
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put in contact on the sample surface, passes from 27 ± 1° for D0 to an average value of 32 ± 1° for the 
quercetin containing samples. After 4 seconds, water was always completely spread on the surface of the 
samples. 
 
5.1.1 Composite crystals obtained through phase transition 
 
In order to study the possible pH effect on quercetin stability and activity, an alternative approach has been 
developed for the synthesis of quercetin modified hydroxyapatite. The reagents are the same as those used in 
the procedure of direct synthesis but the pH is not adjusted, leaving the spontaneous pH of the solutions 
(about 4) and at the temperature of 65°C. The precipitates obtained after 6 days storage in solution are 
constituted of DCPA as unique crystalline phase both in absence and in presence of quercetin. After 6 days 
storage in solution, the pH is adjusted to 9 and the temperature is raised to 90°C, which provokes the 
transformation of DCPA in HA. Indeed DCPA, as well as other orthophosphates, easily hydrolyzes to the 
thermodynamically more stable HA phase, according to a transition mechanism that is favored by basic 
conditions [194]. 
The powder XRD patterns of samples T0, T85 and T170, show the main peaks of crystalline HA. On the 
contrary, the most intense peaks in the XRD pattern of the sample T255 are due to DCPA, indicating that at 
this concentration quercetin inhibits monetite transformation in HA (Figure 24). 
The XRD peaks of the apatitic samples are very sharp and, accordingly, the values of the mean values of the 
length of coherently scattering domains, reported in Table 4, are relatively high and do not exhibit a relevant 
reduction on increasing quercetin content. At the same way, the lattice parameters do not show significant 
variation with composition when compared to HA reference (Table 4). 
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Figure 24 Powder XRD patterns of the products obtained through phase transition [93]. 
  
The amount of quercetin adsorbed on T samples increases up to about 1.3 wt%, a lower value with respect to 
the samples obtained by direct synthesis (Table 4). 
Table 4 Coherent lengths (τhkl) of the perfect crystalline domains in the direction normal to (002) and to (310) planes 
calculated using the Scherrer method; lattice parameters calculated using Rietveld method, Specific Surfaces Area, amount 
of quercetin associated to inorganic phase [93]. 
Samples τ002 (Å) τ310 (Å) a (Å) b (Å) SSA (m
2
/g) Que (wt%) 
T0 570(1) 298(1) 9.4404(4) 6.8848(4) 16(2) - 
T85 565(1) 294(1) 9.4294(4) 6.8758(4) 16(2) 0.5(3) 
T170 556(1) 288(1) 9.4377(5) 6.8818(4) 16(2) 1.3(4) 
 
TEM images reported in Figure 6 show that samples constituted of big rod-like crystals with well defined 
edges and elongated along a preferential direction. The mean dimensions are 300 x 40 nm and the mean 
surface area is 16 m
2
/g  at variance with what found for the samples prepared by direct synthesis, the 
presence of quercetin does not affect significantly the morphology and the dimension of the crystals. 
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Figure 25 TEM images of the products obtained by phase transition (T0, T85 and T170) [93]. 
 
On the other hand, as for the samples obtained by direct synthesis, quercetin does not affect the hydrophilic 
behavior of the composite crystals, which exhibit contact angle values from 26 ± 1° to 32 ± 1° after 0.33 s 
the water droplet contacted the surface. 
The results of full profile fitting of the XRD patterns, for composite crystals obtained by direct synthesis and 
by phase transition, show that there is no significant amount of amorphous material in both cases. Moreover 
the cell parameters, as commented before, do not vary with the composition, suggesting that HA interaction 
with quercetin does not provoke relevant structural modifications. Considering this information, it was 
possible to hypothesize a possible interaction between HA and quercetin dihydrate considering the full 
atomic position set, occupancy factors and thermal parameters.  
In fact in the molecular structure of quercetin, the distances oxygen-oxygen are around 6.4/6.6 nm, which fit 
well with the calcium periodicity of HA along the axis c. According to this structural data, the oxygens of 
quercetin may interact with calcium (I) of hydroxyapatite, without significantly affecting its structure (Figure 
26). 
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Figure 26 Structural model showing a possible interaction between HA and quercetin [93]. 
 
5.1.2 Quercetin oxidation 
 
The photographic images reported in Figure 8 allow to appreciate the color change of the final products as a 
function of the type of synthesis procedure and of flavonoid concentration. 
 
 
Figure 27 Photographic images of the different products [93]. 
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Table 5 Effects of heat treatment, pH and storage condition on quercetin content [195]. 
Food processing Food product Processing condition Results 
 
 
 
 
 
Thermal 
 
 
 
 
 
Bean 
 
 
 
Onion bulbs 
 
 
Solutions 
 
 
Atmospheric (100°C) and 
pressure boiling(121°C) 
with and without soaking 
 
Atmospheric boiling 
(100°C) for 60 min. 
 
Heating at 97°C for 240 
min under pH 8, N2 
 
70% degradation of 
quercetin [197] 
 
 
43% degradation of 
quercetin [198] 
 
15% degradation of 
quercetin [199] 
 
 
 
 
 
Alcali or acid 
 
 
 
 
Grapefruits juices 
 
Solutions 
 
 
 
Solutions 
 
 
Heating at 80°C for 91 sec 
 
Treatment with different 
pH values (pH 5 and 8) for 
300 min 
 
Treatment with different 
pH values (2, 7, 10) for 96 h 
 
17% degradation of 
quercetin [200] 
100% degradation of 
quercetin [201] 
 
 
100% degradation of 
quercetin [202] 
 
 
 
 
 
 
Metal ions 
Solutions  
 
 
Solutions  
 
 
 
Solutions 
Quercetin and CuCl2 
 
 
In the presence of Cr3+ 
 
 
 
In the presence of Sn2+ 
Increase antioxidant 
activity [203] 
 
Increase DPPH 
radical scavenging 
activity [204] 
 
Decrease DPPH 
radical scavenging 
activity [205] 
 
Compared to the white reference HA, the products obtained by direct synthesis in the presence of  quercetin 
display a yellow-brownish color which becomes darker with the increasing of the flavonoid content. On the 
other hand, in the products obtained through phase transition, the color passes from yellow to dark yellow as 
a function of composition. This color variation might be due to quercetin oxidation, which would be 
provoked by the relatively high pH of the synthesis medium. The different color range of the products, 
obtained with the two synthesis methods, might suggest that the quercetin has undergone different 
mechanisms of oxidation  and/or degradation. 
UV-Vis spectrum of quercetin shows two characteristic bands at 256 and 373 nm that are due to the ππ* 
transitions at rings A and B respectively. Upon oxidation, these bands begin to decrease and a further band 
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appears at 295-330 nm. In the experimental UV-Vis absorption spectrum of sample D170, the band at 373 
nm is no more appreciable, whereas the relative intensity of the 256 nm band appears significantly reduced, 
in agreement with a degradation of quercetin (Figure 28). 
 
Figure 28 UV–vis absorption spectra of pure quercetin, D170 and T170 [93]. 
 
In literature several processes have been proposed for the oxidation of quercetin; the one proposed by Wang 
et al [195] might be eligible for these samples. Quercetin can be oxidized into various products, namely 
quercetin-quinones, which include one ortho-quinone and three quinone methides (Figure 29). A cleavage of 
quercetin leading to a protocatechuic acidis is one of the possible degradation of the cynnamoil system.  
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Figure 29 Oxidation and degradation pathways of quercetin [195] 
 
5.1.3 Radical scavenging activity 
 
RSA of the different samples are compared with that of pure quercetin, in the following figure. 
 
Figure 30 Comparison between the antiradical activity, expressed as% RSA, of the different products and that of pure 
quercetin. Each bar represents the mean standard deviation of three independent measurements [93]. 
 
Pure quercetin exhibits RSA values varying from 45% to 50% as a function of concentration, in good 
agreement with previous data [196]. RSA values of the products obtained through direct synthesis are 
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significantly reduced with respect to those of pure quercetin, whereas those obtained for the products 
obtained through phase transition are still very high, reaching levels of about 40%, as shown in Figure 30. 
These data confirm that the antioxidant activity of quercetin is maintained in the apatitic samples obtained 
through phase transition, whereas it is remarkably reduced in the samples prepared by direct synthesis, as 
shown by the results of spectrophotometric analysis. 
On the basis of these results, which demonstrate the good radical scavenging activity of the products 
synthesized through phase transition, in vitro study was performed on samples T85 and T170, as well as on 
T0 as control sample. 
The study was performed utilizing an innovative in vitro model, which involves co-culture of osteoblast, 
osteoclast and endothelial cells. Osteogenesis is closely related to angiogenesis, since a suitable angiogenic 
response is essential for successful bone repair. As a consequence, a triculture model involving the interplay 
of osteoblast, osteoclast and endothelial cell (HUVEC) populations is necessary to mimic bone physiological 
microenvironment.  
 The results demonstrated that hydroxyapatite functionalized with different amounts of quercetin displays 
both the good bioactivity of the inorganic phase and the therapeutic properties of the flavonoid. In fact, in 
vitro data show the quercetin functionalized samples stimulated osteoblast proliferation and activity, down-
regulated osteoclastogenesis, and supported microangiogenetic processes necessary for new bone formation, 
allowing to state that the new materials exert a beneficial action onto bone repair microenvironment. 
 
 
5.2 Calcium Phosphates functionalized with Quercetin. 
 
5.2.1 Hydroxyapatite modified with alendronate  
Hydroxyapatite was synthesized in the presence of alendronate, as previously reported [206]. The XRD 
diffraction pattern of HAAL sample (Figure 31) shows a slight increase of the peaks broadening when 
compared to HA pattern, suggesting that the presence of alendronate provokes just a modest increase of 
disorder.  
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The amount of alendronate incorporated into HA crystals was found to be 7 wt%. Despite the relatively high 
content of alendronate, the values of the lattice constants of the apatitic phase (a = 9.424(1) Å, c = 6.880(1) 
Å), as well as the Ca/P molar ratio (Ca/P = 1.67), are not significantly affected by alendronate incorporation 
[206].  
 
Figure 31 XRD patterns of HA and HAAL 
 
 
5.2.2 HA and HAAL functionalized with Quercetin. 
The powder XRD patterns reported in Figure 32 show that all the products obtained after quercetin 
adsorption are constituted of crystalline hydroxyapatite, independently from the time length of the adsorption 
process. However a peak, of low relative intensity (about 3%), is observable at 27.4 2θ°: it can be assigned to 
quercetin dihydrate phase. The amount of quercetin associated to HAAL samples does not vary as a function 
of time: the maximum amount of adsorbed quercetin (about 5.4 wt%) is reached already at 24h (Table 6).  
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Figure 32 XRD patterns of (a) HA and (b) HAAL maintained in quercetin solution for different times.  
 
Table 6 Quercetin content in the samples obtained with different adsorption times. 
 Que 24h (wt%) Que 48h (wt%) Que 72h (wt%) 
HA 4 5 6 
HAAL 5.4 5.4 5.3 
 
At variance, a modest increase of the amount of adsorbed quercetin as a function of time has been observed 
onto HA samples (Table 6) 
Figure 33 reports the FTIR spectrum of pure quercetin, whereas Table 7 reports the FTIR bands assignment.  
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Figure 33 FTIR spectra of quercetin dihydrate. 
 
 
 
Figure 34 FTIR spectra of HA72Q 
 
 
The most intense bands (1700- 800 cm
-1
) of the flavonoid are present also in the spectra of HA and HAAL 
with adsorbed quercetin. The bands display a lower intensity, but fall in the same positions as in the 
reference spectrum (Figure 34). This result confirms the presence of quercetin on the apatitic crystals and the 
conservation of the flavonoid structure. 
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Table 7 FTIR band assignment of quercetin dihydrate [207, 208] 
Attribution Wavenumber (cm
-1
) 
CCO bending (C) 601 
CCO bending (C) 637 
CCO bending (B) 678 
CCO bending (A,B) 724 
CCC bending (b) (C3-C4-C5) 760 
CCC bending (B) 797 
CCO bending (C)/ COC bending (C) 823 
CCO bending (C)/ COC bending (C) 844 
HCC bending (A,B) 941 
HCC bending (A,B) 1013 
COH bending (C) 1090 
COH bending (B) (C2-OH) 1130 
CCO bending (C) 1168 
CC stretching (C,B)/  COH bending (A,C)/ HCC 
bending (A) 
1196 
OC stretching (B) (C2-O) 1216 
CC stretching (C,B)  /  COH bending (C) (C3-
OH) 
1262 
OC stretching (B/)  COH bending (B) (C2-
OH,C4-OH) 
1313 
CC stretching (A)  /COH bending  (B) (C4-OH) 1383 
CC stretching (A) / CCO bending (A,C) 1410 
CC stretching (A) / CCO bending (A,C) 1446 
C=O stretching / CCC bending (B) (C2-C3-C4) 1523 
C=O stretching  / COH bending B (C5-OH) 1562 
CC stretching (B) 1616 
CC stretching (C)  (C2-C3) /  OC stretching 
(A,C) 
1664 
CH stretching (B) 2850 
CH stretching (B) 2961 
OH stretching C2-OH 3101 
OH stretching 3244 
OH stretching C,B 3313 
OH stretching C,B 3384 
OH stretching (A) C4-OH 3580 
 
The antioxidant activity of these composite materials was evaluated through analysis of the radical 
scavenging activity, expressed as % RSA, which was performed on all the HA and HAAL samples modified 
with quercetin (Figure 35, 36). The test was performed on solutions at different concentrations, in order to 
analyze the effect of increasing amounts of quercetin. The solutions exhibited slightly different values of pH 
as a function of concentrations (Table 8); the pH of the solutions of pure quercetin was adjusted accordingly, 
in order to examine comparable data. 
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Table 8 pH of the solutions used to perform RSA analysis. 
 10µM 30µM 50µM 100µM 
HAQ 2.32 2.46 2.70 3.15 
 
 
Figure 35 Comparison between the antiradical activity, expressed as% RSA, of the different products and that of pure 
quercetin. Each bar represents the mean standard deviation of three independent measurements. 
 
 
Figure 36 Comparison between the antiradical activity, expressed as% RSA, of the different products and that of pure 
quercetin. Each bar represents the mean standard deviation of three independent measurements. 
 
Pure quercetin exhibits RSA values varying from 10% to 60% as a function of concentration. RSA values of 
the HAQ and HAALQ samples are generally similar to those of pure quercetin, with the exception of the 
data relative to 50 μM concentration. These data confirm that the antioxidant activity of quercetin is 
maintained in both HAQ and HAALQ samples. 
0
10
20
30
40
50
60
70
80
QUE HA24Q HA48Q HA72Q
R
SA
%
 10µM
30µM
50µM
100µM
0
10
20
30
40
50
60
70
80
QUE HAAL24Q HAAL48Q HAAL72Q
R
SA
%
 10µM
30µM
50µM
100µM
79 
 
5.2.3 DCPA and SrDCPA functionalized with Quercetin. 
The powder XRD patterns reported in Figure 37 show that the products maintained in quercetin solutions for 
different times are constituted of crystalline monetite.  Also in this case, the presence of a low intensity peak, 
at 27.4 2θ°, indicates the presence of quercetin dihydrate. The amount of quercetin associated at each 
samples increases slightly as a function of adsorption time (Table 9).  
Performing this adsorption on DCPA, the crystallinity of the product was influenced by the presence of the 
ethanol and by the time of contact. To evaluate this influence, DCPA powder was put in contact with ethanol 
solution in the absence of quercetin for 24 and 72 hours. The XRD patterns show that the sharpness of the 
calcium phosphate peaks increases as function of exposure time (Figure 38) and so presumably does 
crystallinity. 
 
Figure 37 XRD patterns of (a) SrDCPA and (b) DCPA maintained in quercetin solution for different times. 
 
(a) (b) 
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Table 9 Quercetin content of DCPA and SrDCPA samples at different adsorption times 
 Que 24h (wt%) Que 48h (wt%) Que 72h (wt%) 
DCPA 3 3.7 4.4 
SrDCPA 4 4 5.2 
 
The FTIR spectra of  DCPA and SrDCPA with quercetin, show the most intense bands (1700- 800 cm-1) of 
the flavonoid, which display a lower intensity and no appreciable shift  with respect to those of the reference 
spectra (Figure 34). Figure 39 reports the FTIR spectra of the sample DCPA72Q. This result confirms the 
presence of quercetin on the apatitic crystals and the conservation of the flavonoid structure. 
The FTIR bands attributions of monetite are reported in Table 10 
 
Figure 38 XRD patterns of DCPA after incubation in ethanol solution. 
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Table 10 FTIR bands of monetite [209]. 
Wavenumbers (cm
-1
) Attribution 
893 P-O(H) stretching 
996 P-O stretching 
1070 P-O stretching 
1132 P-O stretching 
1353 O-H in plane bending 
1652 O-H in plane bending 
2369 P-O-H stretching 
3216 O-H stretching 
3415 O-H stretching 
 
 
 
 
 
 
 
 
 
Figure 39 FTIR spectra of DCPA72Q 
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Figure 40 SEM images of DCPA and SrDCPA before and after quercetin adsorption. 
 
SEM analysis shows that DCPA and SrDCPA crystals exhibit well defined edges and twinning.. After 
flavonoid adsorption, the crystals appear splitted in smaller ones with ill-defined edges, most likely  affected 
by the stirring used for the adsorption experiments Figure 40).  
The values of RSA of the different samples are compared with that of pure quercetin, determined at different 
values of pH (Table 11), in Figures 41 and 42. 
 
 
Table 11 pH of the solutions used to perform RSA analysis 
sample 10µM 30µM 50µM 100µM 
DCPAQ 2.23 2.33 2.48 3.03 
 
83 
 
 
Figure 41 Comparison between the antiradical activity, expressed as% RSA, of the different products and that of pure 
quercetin. Each bar represents the mean standard deviation of three independent measurements. 
 
 
 
Figura 42 Comparison between the antiradical activity, expressed as% RSA, of the different products and that of pure 
quercetin. Each bar represents the mean standard deviation of three independent measurements. 
 
The trend is similar to that previously observed for the apatitic samples (Figures 35 and 36) and confirms 
that the antioxidant activity of quercetin is maintained also in these samples. 
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5.3 Octacalcium phosphate functionalized with alendronate and zoledronate 
The aim of this study is the functionalization of octacalcium phosphate with alendronate and zoledronate, in 
order to obtain new biomaterials for the local treatment of diseases characterized by abnormal bone loss. In 
fact, the possibility to functionalize OCP with BPs through co-precipitation in order to couple the good 
biological performance of OCP with the therapeutic properties of bisphosphonates has not been explored up 
to now. 
The results of XRD analysis show that functionalization of OCP with alendronate can be obtained up to a 
bisphosphonate concentration in solution of 1.2 mM. In fact the XRD patterns of the products exhibit the 
presence of octacalcium phosphate, as unique crystalline phase, up to sample OAL1.2. At variance, the XRD 
pattern of the sample OAL1.5 shows also the presence of a little amount of crystalline calcium alendronate 
[210], as evidenced by the presence of two additional peaks at about 9.1° and 12.8° of 2θ ( indicated by 
symbols in Figure 43). 
 
Figure 43 X-ray diffraction patterns of the products synthesized in the presence of increasing concentrations of alendronate 
and  zoledronate, compared with that of pure OCP. The symbols indicate the presence of crystalline calcium alendronate 
() and calcium zoledronate() [189]. 
 
The structure of OCP is not significantly affected by the presence of AL, in agreement with the absence of 
significant variations in the values of the lattice parameters, which are close to those calculated for pure OCP 
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(Table 12). At variance, the broadening of the diffraction reflections displays a modest increase with the 
increasing of alendronate content, suggesting a reduction of the crystallinity degree. 
 
Table 12 Cell parameters (e.s.d. in parentheses) of  OALXX samples which showed octacalcium phosphate as unique 
crystalline phase [189]. 
 a (Å) b (Å) c (Å)  (°)  (°)  (°) 
OCP 19.722(3) 9.552(2) 6.847(1) 90.13(1) 92.56(2) 108.28(1) 
OAL0.1 19.733(8) 9.564(4) 6.855(2) 90.16(4) 92.58(5) 108.24(4) 
OAL0.3 19.706(3) 9.542(1) 6.841(1) 90.13(1) 92.55(1) 108.25(1) 
OAL0.6 19.709(3) 9.547(2) 6.842(1) 90.15(1) 92.55(2) 108.26(1) 
OAL0.9 19.720(3) 9.553(1) 6.847(1) 90.15(1) 92.54(2) 108.26(1) 
OAL1.2 19.722(3) 9.552(1) 6.845(1) 90.15(1) 92.54(1) 108.26(1) 
 
 
A qualitative estimation of the size of the coherently scattering domains (i.e. the crystallite size) was 
performed from the line broadening of the 100, 002 and 010 reflections. The lengths of the coherent domains 
(hkl), calculated using the Scherrer equation, are showed in table 13. 
Table 13 Coherent lengths (τhkl) of the perfect crystalline domains in the direction normal to (100), (002) and to (010) planes 
calculated using the Scherrer method; zeta potential (); and bisphosphonate content [189]. 
 
 
 
 
 
 
 
 
 τ100 (Å) τ002 (Å) τ010 (Å) (mV) 
BP content 
(wt%) 
OCP 545(21) 816(48) 604(21) -7.8 -- 
OAL0.1 530(49) 796(41) 617(10) -3.0 3.0 
OAL0.3 515(40) 759(62) 606(18) -2.0 3.2 
OAL0.6 508(26) 777(83) 667(22) -3.1 3.6 
OAL0.9 487(42) 727(70) 586(17) -3.9 4.3 
OAL1.2 468(33) 742(61) 557(15) -3.6 5.2 
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The data reported in Table 13 show that on increasing alendronate concentration, hkl values display a general 
trend to decrease. The amount of alendronate contained in the solid products increases from a minimum 
value of 3.0 wt%  up to a maximum value of about 5.2 wt%. .  
SEM images show plate like crystals, which exhibit a morphology typical of OCP. Moreover, it is evident 
the reduction of the mean dimensions of the crystals with the increase of alendronate content. The relative 
size histograms, reported in Figure 44, show that the decrease of the mean size is greater along the width of 
the crystals than along their length. Accordingly, the length/width ratio passes from about 10 to about 15 on 
going from pure OCP to OAL1.2, suggesting a preferential interaction of alendronate with the (0k0) faces of 
OCP structure.  
Table14. Mean length and width values of OCP and OALXX crystals as measured from SEM observations. T Student test 
was employed to assess statistical significant differences vs. OCP  (* p<0.05; ** p<0.001) [189]. 
 
 
The zeta potential of OCP was found to be -7.78 mV, in agreement with the basic pH of the solution (about 
8.5) [211]. The zeta potential values of the samples containing alendronate are slightly higher than that of 
pure OCP, without showing any significant variation as a function of alendronate content, as shown in Table 
13. 
These results could be related to the data on alendronate release. Figure 45 shows that, in the first 10 hours, 
all OALXX samples display a fast release, after which they reach constant alendronate content. On this basis, 
it can be suggested that a great part of alendronate is weakly bound to OCP crystals and easily lost in 
solution, whereas the part retained in the solid products involves a stronger interaction with the calcium 
phosphate. After release, the different samples exhibit similar values of alendronate content (about 1.5 wt 
%), which could justify the similar values of zeta potential.  
 
 Mean Length (µm) Mean Width  (µm) Length/Width 
OCP 71.95 ± 26 6.75 ± 2 10.66 
OAL0.6 40.55 ± 21 3.99 ± 2 10.16 
OAL0.9 42 ± 18 3.29 ± 1 12.76 
OAL1.2 32.69 ± 12 2.16 ± 1 15.13 
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Figure 44 SEM images of the products synthesized in the presence of increasing concentrations of alendronate compared with 
that of pure OCP. The histograms show the size distribution along the length and the width of the crystals [189]. 
 
 
 
Figure 45 Alendronate and zoledronate release from the different samples as a function of time [189]. 
 
The range of zoledronate concentration which allowed to obtain OCP as a single crystalline phase is lower 
than that verified for alendronate. In fact, the XRD patterns (Figure 46) show that OZOL0.9 contains also a 
88 
 
second phase, as supported by the presence of three additional peaks at 9.6, 13.2 and 18.6 ° of 2, which 
correspond to the most intense peaks of crystalline calcium zoledronate [120].  
SEM images of the sample OZOL0.9 show big plate-like crystals characteristic of OCP mixed with  very 
small thin elongated crystals, supporting the information obtained by XRD analysis about the presence of a 
second crystalline phase (Figure 46). OCP crystals synthesized in the presence of zoledronate tend to 
aggregate: SEM images of all ZOLXX samples show the presence of both separate crystals and spherulites, 
with the relative amount of aggregates increasing with increasing ZOL content (Figure 4). Moreover, 
histograms in Figure 46 show an increase of the length/width ratio with respect to that of OCP, similar to 
what observed for OALXX samples, caused by the variation of crystal dimensions on increasing ZOL 
content in solution.  
 
 
Table 15  Mean length and width values of OCP and OZOLXX crystals as measured from SEM observations. T student test 
was employed to assess statistical significant differences vs. OCP (* p<0.05; ** p<0.001) [189]. 
  
 
Zoledronate content in the solid products increases with its concentration in solution, up to about 3.5 wt% 
(Table 16). As observed for alendronate, the lattice parameters are not influenced by the incorporation of 
zoledronate, whereas the mean lengths of the coherently scattering domains along the crystallographic 
direction 100, 002 and 010 significantly reduce.  
 
 Mean Length (µm) Mean Width  (µm) Length/Width 
OCP 71.95 ± 26 6.75 ± 2 10.66 
OZOL0.1 76.65 ± 28 5.28 ± 2 14.52 
OZOL0.3 55.46 ± 23 4.30 ± 1 12.90 
OZOL0.6 26.98 ± 11 2.005 ± 1 13.46 
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Figure 46 SEM images of the products synthesized in the presence of increasing concentrations of zoledronate. The 
histograms show the size distribution along the length and the width of the crystals [189]. 
 
Table 16 Coherent lengths (τhkl) of the perfect crystalline domains in the direction normal to (100), (002) and to (010) planes 
calculated using the Scherrer method; zeta potential (); and bisphosphonate content [189]. 
Sample τ100 [Å] τ002 [Å] τ010 [Å] [mV] BP content 
[wt%] 
OCP 545(21) 816(48) 604(21) -7.8 -- 
OZOL0.1 547(29) 726(65) 581(15) -16.0 1.3 
OZOL0.3 500(33) 595(32) 538(19) -17.3 2.4 
OZOL0.6 487(32) 573(40) 518(15) -20.0 3.5 
 
 
Table 17 Cell parameters (e.s.d. in parentheses) of OZOLXX samples which showed octacalcium phosphate as unique 
crystalline phase [189]. 
 a (Å) b (Å) c (Å)  (°)  (°)  (°) 
OCP 19.722(3) 9.552(2) 6.847(1) 90.13(1) 92.56(2) 108.28(1) 
OZOL0.1 19.734(4) 9.557(2) 6.848(1) 90.14(2) 92.57(2) 108.29(2) 
OZOL0.3 19.718(6) 9.547(2) 6.845(1) 90.14(2) 92.55(3) 108.22(2) 
OZOL0.6 19.737(3) 9.560(2) 6.849(1) 90.15(1) 92.54(1) 108.27(1) 
 
90 
 
 
The graph in Figure 45 show that OZOLXX composite samples do not show appreciable BP release in 
solution, at variance with the results obtained for OALXX samples. This result can be explained with the 
stronger interaction that zoledronate has with OCP structure. The stronger binding affinity of the two 
bisphosphonates towards hydroxyapatite was previously justified by the possibility of  ZOL to form two H 
bonds with HA structure and by the availability of a favorable Ca ions coordination geometry [212, 213].  
In particular, these N-H-O hydrogen bonds can be formed at two different sites on HA and, for optimal 
binding, an N-H-O angle ≥125° and an N-O distance of about 3 Å is required. One H binding site can occur 
at a hydroxyl coordinated to the second type of calcium (CaII) in HA.  
The -NH2  group of alendronate is able to form this N-H-O bond because of its structure (132°, 2.7 Å N-O 
distance).  
A second H bonding interaction can occur at a neighboring calcium (CaI), which can optimally allow a 
bifurcated dual bonding arrangement, as predicted by the zoledronate N-H-O bonding angles and distances 
with its distal heteroaromatic nitrogen [212]. 
 
 
 
Figure 47 Molecular modeling: bisphosphonates binding to hydroxyapatite. An electrostatic surface representation of HAP 
with the key binding residues of Zoledronate and Alendronate [212]. 
   
 
Considering that OCP and hydroxyapatite are structurally similar, the same argument can be extended to 
discuss the different interaction of ZOL and AL with OCP. A sketch of possible interactions between OCP 
structure and BPs is reported in Figure 48. 
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The values of zeta potential of ZOLXX samples reduce significantly on increasing BP content, down to -20 
mV (Table 16). A similar effect of zoledronate on zeta potential was previously reported for hydroxyapatite 
crystals at different ZOL content; the shift of the zeta potential towards negative values was interpreted as 
due to the binding of negatively charged phosphonate groups to Ca
2+
 sites on the surface of hydroxyapatite, 
which becomes more negative [214]. Previous results on the different influence of zoledronate and 
alendronate on the zeta potential of hydroxyapatite as a function of BPs concentration in solutions [121] 
were justified on the basis of the different pKa of AL and ZOL functional groups.   
Hydrolysis test was carried out on pure OCP and the obtained powders were controlled using X-ray 
diffraction analysis.  The results show that, after three days storage in solution at pH 7.4 at 60°C, 
octacalcium phosphate is completely converted into HA (Figure 49). On the contrary, the composite 
OALXX and OZOLXX crystals do not exhibit any conversion into HA even after 30 days (Figure 50), 
indicating that the presence of BPs prevents the hydrolysis reaction.  
 
 
 
Figure 48 Scheme of possible structural interaction between alendronate or zoledronate molecules and the crystalline structure 
of OCP [189]. 
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Figure 49 Powder X-ray diffraction patterns of the solid products obtained after OCP storage in aqueous solution at pH 7.4 
and 60°C, plotted as a function of storage time [189]. 
 
 
Figure 50 Powder X-ray diffraction patterns of the solid products obtained after OALXX and OZOLXX storage in aqueous solution 
at pH 7.4 and 60°C, after 30 days of storage time [189]. 
 
These results can be explained looking the two limiting equations for the hydrolysis reaction depending on 
the availability of calcium ions in the solution, proposed by Brown et al [215] 
 
  
 
 Ca8H2(P04)6 * 5 H20 (xtal)  →  2 Ca5(PO4)3OH (xtal) + 
 
 
 H3PO4(soln) + 
  
 
  H20 (soln)        (1) 
Ca8H2(PO4)6 * 5 H20 (xtal) + 2 Ca
2+(soln) → 2 Ca5(PO4)30H (xtal) + 4 H
+
(soln) + 3H20 (soln) (2) 
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It can be seen from equation (1) that 20% of the phosphate is lost to the solution in the absence of calcium 
ions in the solution and this loss probably affects the kinetics of the reaction.  
If the calcium ions are not easily available, the reaction is likely to fall somewhere between equations (1) and 
(2). At the same time, the apatitic product may be calcium deficient. It has been observed that the hydrolysis 
process does not go to completion. This indicates that the mechanisms for diffusion of calcium ions into the 
hydrolyzing crystal and those for removing water molecules and hydrogen ions are inadequate and lead to 
the retention of OCP in the crystals. 
In the case of OALXX and OZOLXX samples, calcium ions might be sequestered by BPs because of their 
high affinity with it, blocking the hydrolysis reaction. 
On the other hand, BPs do not influence the thermal stability of OCP. The XRD patterns recorded from pure 
OCP at increasing temperatures show the onset of a shoulder next to the (100) small angle reflection at 4.7° 
2, together  with a variation towards an apatitic pattern in the higher angles region. Above 200°C, the split 
of the low angle reflection in two peaks and the onset of a new peak at 5.2 ° 2 suggest the presence of a 
further phase, previously identified as “collapsed OCP” [216], whereas above 250°C the pattern displays the 
characteristics of a poor crystalline apatitic phase. The same trend is observable for OALXX and OZOLXX 
samples, as shown in Figure 51 for the sample OZOL0.6. 
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Figura 51 Powder X-ray diffraction patterns of OZOL0.6 recorded in situ at increasing temperature up to 300 °C (right) and 
high magnification of the small angle region (left) [189]. 
 
Bone cells response of the synthesized materials was tested in vitro using a triculture model involving 
osteoblasts (OB), osteoclast (OC) and endothelial cells (HUVEC) in order to mimic bone microenvironment.  
In order to avoid morphology influence on cell response, the tests were performed on disk-shaped which do 
not present significant surface difference as a function of composition and similar roughness parameters, 
Ra=0.178±0.014 μm, Rq= 0.220±0.022 μm, Rt=1.681±0.065 μm.  
The results of the triculture tests indicate that BP functionalized samples downregulate the viability 
of the cells, sustain osteoblast differentiation and accelerate the production of collagen type I and 
osteocalcin. At variance, they inhibit monocyte differentiation into osteoclast and provoke a dose 
dependent reduction of VEGF production, exhibiting antiresorptive and anti-angiogenetic properties 
that can be usefully exploited for the local treatment of abnormal bone losses [189]. 
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5.4 Hydroxyapatite functionalization as a tool to modulate adsorption and release of risedronate. 
Calcium phosphates (CaPs) have been largely suggested as supports for the local administration of 
bisphosphonates (BPs), because of their biocompatibility and bioactivity and of the great affinity that BPs 
display for them [213, 217-223]. 
CaPs functionalized with BPs can be prepared through adsorption from solution, as reported in literature 
[220, 213, 223], but it has been demonstrated that the structure and the composition of the apatitic surface 
play a fundamental role on the mechanism of adsorption and desorption process, influencing adsorption 
parameters and the kinetic of release of bisphosphonate [223-225].    
On this basis, in this study HA with a partial substitution of zinc to calcium (ZnHA), HA and ZnHA 
functionalized with polyethyleneimine (HAPEI, ZnHAPEI), as well as HA as control material, were utilized 
to investigate the role of composition and surface charge of hydroxyapatite on the adsorption and release 
mechanisms of risedronate. 
The polycationic polymer PEI should enhance the positive charge the surface of the apatitic nanaocrystals, 
promoting the adsorption of negatively charged BP from solution and controlling its release. On the other 
hand, cationic substitution in HA can influence crystal growth and influence specific surface, modifying 
adsorption capability. 
The adsorption of risedronate on these supports and the relative release mechanisms were investigated in 
order to understand the interaction of BP with the apatitic supports. 
 
5.4.1 Characterization of HA, HAPEI, ZnHA and ZnHAPEI substrates 
 
The amount of PEI associated to the apatitic phase was determined through thermogravimetric analysis 
(Figure 52): it increases as a function of concentration in solution up to about 2.5 wt%. 
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Figure 52 Thermogravimetric plots of the apatitic samples synthesized in the presence of increasing PEI concentration in 
solution (1 M, 2 M and 4 M of PEI) [186]. 
The powder XRD patterns reported in Figure 53 show that the products obtained through the synthesis of HA 
in the presence of different PEI concentrations in solution, namely 1, 2 and 4, are constituted of 
hydroxyapatite as unique crystalline phase. Observing the XRD patterns of the HAPEI samples, it’s evident 
that the sharpness of the diffraction peaks increases on increasing PEI concentration, which suggests an 
increase of crystallinity of the apatites precipitated in the presence of the polymer. 
 
Figura 53 Powder X-ray diffraction patterns of the apatitic samples synthesized in the presence of increasing PEI 
concentration in solution (1 M, 2 M and 4 M of PEI) [186]. 
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The increase of crystallinity, related to the PEI content in the different samples, is confirmed also by 
RAMAN analysis, as shown in Figure 54. The Raman spectra not only show the characteristic bands of 
apatite, reported in Table 18, but also the presence of the bands of  the polymer, which display an increase of 
intensity with the increasing of PEI content in the samples. The PEI characteristic bands are between 2800 
cm
-1
 and 3200 cm
-1
 and they can be attributed to the stretching vibration of the CH and CH2 groups. 
 
Table 18   Raman bands of apatite [226] 
Attribution Raman (cm
-1
) 
ν2 PO4 432 
452 
 
ν4 PO4 
584 
590 
611 
P-OH, HPO4 1004 
873 
ν1 PO4 961 
 
ν3 PO4 
1005 
1032 
1044 
1071 
ν1 CO3      Type A 
             Type B 
1071 
1103 
 
 
 
 
Figure 54 Raman assignments for apatite 
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Figure 55 Raman spectra of the apatitic samples synthesized in the presence of increasing PEI concentration in solution (1 M, 
2 M and 4 M of PEI) [186]. 
 
The FTIR spectra show no relevant differences among the samples at different amount of PEI, however the 
spectral decomposition in the 400-800 cm
-1
 vibration domain displays an enhancement of the relative 
intensity of the OH band, on passing from HA to HAPEI 4. This result, in agreement with Raman and XRD 
analysis, confirms the increase of crystallinity as function of PEI content. Ratios of bands integrated 
intensities were used to follow the evolution of spectral features, taking the sum of apatitic phosphate bands 
as a reference, as shown in the following formula.  
                                       
            
                
               
           
 
 
For these mathematical decompositions, based on Kauppinen’s methodology [227], the bands were 
considered as Lorentzian in shape. Ratios of bands integrated intensities were used to follow the evolution of 
spectral features, taking the sum of apatitic phosphate bands as a reference. The FTIR bands used for this 
analysis and the others characteristic of apatite are reported in Table 19. 
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Figure 56 Mathematical decomposition of the FTIR bands in the range400-800 cm-1 
 
 
Table 19 Attribution of FTIR bands of apatite 
Attribution 
 
Wavenumbers (cm
-1
) 
ν2 PO4 469 
HPO4 non apatitic 533 
HPO4 apatitic 551 
ν4 PO4 antisymmetric bending PO43- 562, 575, 603 
PO4 non- apatitic 617 
νL OH vibration of OH
-
 633 
HPO4 stretching P-OH 873 
ν1 PO4 962 
ν3 PO4 symmetric stretching PO4
3-
 1006, 1020, 1031, 1044, 1059, 1072, 1091, 
1104 
 
HPO4 1144 
 
 
In particular, the principal FTIR bands are those of the apatitic phosphate groups: the multiple bands between 
1006 cm
-1
 and 1104 cm
-1
 correspond to the antisymmetric stretching mode v3 and the band at 962 cm
-1
 
corresponds to the symmetric stretching v1. 
The bands of the bending mode of the PO4
3-
 group are between 562 cm
-1
 and 617 cm
-1
 (ν4) and at 469 cm
-1
 
(ν2). 
When apatite is not stoichiometric the hydrogen phosphate groups are detected at 551 cm
-1
, 870 cm
-1
 and 
1144 cm
-1
 .  
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The lengths of the coherent domains (hkl), in particular τ002, which is related to the mean crystallite size 
along the c-axis, and τ310, which it refers to the mean crystallite size along a direction perpendicular to c-axis, 
and the values of microstrain () were calculated from the microstructure parameters of X-ray diffraction 
pattern refinement procedure. The results show that the coherent length of the perfect crystalline domains 
increases significantly both along the c-axis direction and, even more, along the orthogonal direction on 
increasing PEI content in the solids (Table 20). At variance, the values of microstrain are of the order of 10
-4
 
and do not change appreciably as a function of composition. In agreement with the increase of crystallinity, 
the lattice parameters exhibit a slight but significant reduction of the a-axis on increasing PEI content. 
Table 20 Lattice parameters, coherent lengths (Lhkl) of the perfect crystalline domains and microstrain (ε hkl) in the 
direction normal to 002 and to 310 planes; PEI content, zeta potential and Ca/P molar ratio of the apatitic samples 
synthesized in the presence of PEI [186]. 
 HA HAPEI 1 HAPEI 2 HAPEI 4 
a (Å) 9.4318(3) 9.4358(2) 9.4299(2) 9.4298(2) 
c (Å) 6.8862(2) 6.8903(3) 6.8855(2) 6.8872(2) 
L002 (Å) 657(4) 667(5) 749(6) 929(7) 
L310 (Å) 311(3) 358(3) 405(4) 543(5) 
ε 002 (*10
-4
) 9.9(8.5) 6.9(5.1) 6.9(2.7) 5.9(7.0) 
ε 310 (*10
-4
) 6.0(1.2) 4.6(1.2) 6.2(2.3) 6.8(4.8) 
PEI content  
(wt%) 
--- 0.9(0.5) 1.7(0.5) 2.4(0.5) 
zeta potential (mV) - 15.6 + 19.5 + 24.2 + 26.2 
Ca/P 1.67 1.67 1.67 1.73 
 
TEM images show that the morphology of the composite nanocrystals is influenced by PEI.  In fact, the 
HAPEI nanocrystals display a shorter mean length and a greater thickness when compared with HA ones 
(Figure 57). On the basis of their increased thickness and coherent length of perfect crystalline domains, 
HAPEI nanocrystals could be suggested to be indeed mesocrystals [228] made up of nanoparticles of HA 
aligned by PEI. In fact, PEI interacts preferentially with the hydroxyapatite crystal faces parallel to the c-axis 
and promotes the oriented attachment of nanoparticles, which leads to the observed increased thickness. 
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Figure 97 TEM images of the samples obtained by synthesis with PEI, at different concentration. 
 
In general, when an organic matrix is present, there are two ways for the formation of nanocrystals as the 
building blocks of mesocrystals. In one case, the nanocrystals are generated first. They then attach to the 
organic matrix and get oriented. In another case, the organic matrix provides a heterogeneous nucleation site 
for the nanocrystals. A sketch that explains the nanocrystal alignment by an oriented organic matrix [229] is 
reported In Figure 58. 
However, in the case of HAPEI the morphological variation does not provoke significant modification of the 
superficial area, which is similar to that of pure HA (Table 21). 
The zeta potential of HA is -15.6 mV but the presence of PEI confers positive charge to the samples, which 
increases as a function of the content of the polycationic polymer (Table 21). 
Finally, chemical analysis of HA powder gave a Ca/P ratio of 1.67 characteristic of stoichiometric 
hydroxyapatite. 
At variance, ZnHA nanocrystals exhibit more perturbed shape, ill-defined edges and significantly reduced 
dimensions (Figure 59), as well as a remarkably increased superficial area (Table 21). HA crystal growth is 
inhibited by the presence of Zn in solution [51, 60] and, as consequence, the XRD pattern shows a 
broadening of the diffraction reflections of ZnHA with respect to those of HA (Figure 60). Accordingly, the 
coherent lengths of the perfect crystalline domains of ZnHA evaluated from the line broadening of the 002 
and 310 reflections are significantly reduced with respect to those of pure HA (Table 21). 
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Figure 58 Scheme for the formation of mesocrystals . 
 
Zn amount  into HA nanocrystals is about 7.9 atom % and provokes a reduction of the lattice parameters, in 
agreement with its smaller ionic radius with respect to that of calcium [230]. Samples obtained by adsorption 
of PEI on ZnHA nanocrystals, named ZnHAPEI, do not show significant differences with respect to ZnHA 
in terms of morphology (Figure 59),  coherent lengths of the perfect crystalline domains and lattice 
parameters. Instead, the amount of adsorbed PEI, as well as the value of zeta potential (Table 21), are 
considerably higher than those of HAPEI. 
 
 
Table 21 Lattice parameters, coherent lengths (τhkl) of the perfect crystalline domains in the direction normal to 002 and to 
310 planes; Specific surface areas (SSA); Zeta potential; PEI and Zn content of the different apatitic samples synthesized 
[186]. 
 a (Å) c (Å) L 002 
(Å) 
L 310 
(Å) 
PEI 
content 
(wt %) 
Zn 
content 
(at %) 
SSA 
(m
2
/g) 
Zeta 
potential 
(mV) 
HA 9.4378(3) 6.8862(2) 657(4) 311(3) --- --- 23 - 15.6  
HAPEI  9.4298(2) 6.8872(2) 929(7) 543(5) 2.4 --- 26 + 26.2 
ZnHA 9.4241(9) 6.8696(2) 367(4) 148(3) --- 7.9 86 - 15.3 
ZnHAPEI 9.4238(5) 6.8691(4) 365(5) 152(4) 5.9 7.9 86 +30.9 
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Figure 59 TEM images of the different apatitic samples : HA, HAPEI, ZnHA, ZnHAPEI. 
 
 
 
Figure 60 Powder X-ray diffraction patterns of HA, HAPEI and ZnHA [186]. 
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5.5.2 Risedronate adsorption and characterization 
 
The evolution of the amount of risedronate adsorbed on the solids, Qads (mol/m
2
), from the dilute solutions 
as a function of the equilibrium BP concentration Ceq (0-2 mM) is plotted in Figure 61.  
 
 
Figure 61 Adsorption isotherms of risedronate on hydroxyapatite (HA), Zn-substituted hydroxyapatite (ZnHA), PEI-
modified hydroxyapatite (HAPEI) and PEI modified Zn-substituted hydroxyapatite (ZnHAPEI) at pH 7.4 and 37°C. The 
data fit the Langmuir isotherm. 
 
The isotherms obtained for HA and ZnHA are Langmuirian in shape (r
2 
= 0.87 and 0.94, respectively) 
showing a high affinity of risedronate for the apatitic surface, because the plateau is reached at relatively low 
equilibrium concentrations (below 1 mM). Similar observations have been reported in literature for the 
adsorption of bisphosphonate molecules, as risedronate and tiludronate, on apatitic support [223-225].  
Because of the higher specific surface area of ZnHA (86 m
2
/g) compared with that of HA (23 m
2
/g), the 
risedronate content reached at plateau in presence of HAZn was more than twice as much as that obtained for 
HA, (about 40 and 100 mol/g for HA and HAZn, respectively) (Table 23). The uptake of risedronate 
depended linearly on the amount of released phosphate ions in solution (Figure 62). Thereby, the adsorption 
of risedronate on HA can be described as a chemisorption corresponding to an ion exchange process between 
bisphosphonate molecules in solution and phosphates species on HA. The slope of the curve is close to 1 for 
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HA and it increases for ZnHA. Indeed the number of phosphate groups released per adsorbed risedronate 
molecule varies as a function of the characteristics of the apatitic support, as observed in previous studies on 
BPs adsorption on apatitic substrates [223-225,231]. It can be noticed that the calcium and zinc 
concentrations in the supernatants after adsorption were low and not affected by the adsorption of risedronate 
(below 0.5 mM Ca concentrations for HA and HAPEI; below 0.5 mM and 2 mM for Zn and Ca 
concentrations respectively for ZnHA and ZnHAPEI). 
The parameters of adsorption can be determined from the Langmuir equation (1), (Table 22): 
            (    )      (1) 
where N corresponds to the maximum amount adsorbed of risedronate (mol/m2) and K is the affinity 
constant of risedronate for the solid surface (L/mmol). The values of N and K obtained for the HA and 
ZnHA supports are (Table 5): 1.88  0.05 and 1.20  0.08 mol/m2, respectively, which correspond to the 
values previously obtained for the adsorption of risedronate molecules on apatitic surface [223]. At the same 
time, a significant decrease of the affinity K parameter is observed for ZnHA (7  1 L/mmol) compared with 
HA (21  3 L/mmol) and it can be related to changes in chemical composition. 
 
Figure 62 Concentration of phosphate ions in supernatants after adsorption of risedronate on HA, ZnHA, HAPEI and 
ZnHAPEI 
 
The isotherm of adsorption of risedronate on HAPEI can also be described by the Langmuir model (r
2 
= 0.99). The amount adsorbed at saturation, N, was higher on HAPEI (7.9  0.4 mol/m2) than on HA 
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and ZnHA but the curve does not reach a plateau even at high equilibrium concentrations in solution 
(Ceq). This can be due to the competition of two mechanisms: a chemisorption process on HA surface 
and a physisorption process on PEI coating. The decrease of the affinity K for HAPEI (2.2  0.3 
L/mmol) (Table 22) can be justified by the presence of PEI on the apatitic surface. The evolution of 
the amount of risedronate adsorbed as a function of phosphate released in solution is still linear, but 
the slope appears lower than for HA. The ion exchange process proposed to occur at the surface of the 
apatite seems to be affected by the presence of PEI. The number of phosphate groups released per BP 
molecule is lower in the presence of PEI, in agreement with the presence of two different mechanisms 
of adsorption: chemisorption, which provokes phosphate release, and physisorption, which does not 
provoke ion exchange. On the other hand, the isotherm of adsorption of risedronate on ZnHAPEI can 
be described by Freunlich model (r
2
=0.82 and n <1). The value of affinity constant K is the lowest 
compared to the other isotherms and is present also a low quantity of adsorbed risedronate. The 
simultaneous presence of zinc and polymer might affect the adsorption capacity of the support but the 
fact that 1/n value is above one could suggest a cooperative adsorption process.  
 
Table 22 Adsorption parameters of risedronate on HA, ZnHA and HAPEI, i.e. maximum amount at saturation (N) and 
apparent affinity constant (K) calculated from Langmuir equation plots [186]. 
 N  N (mol.m-2) K  K (L.mmo1-1) 
HA 1.88  0.05 21  3 
ZnHA 1.20  0.08 7  1 
HAPEI 7.9  0.4 2.2  0.3 
ZnHAPEI 
 
- 1.4  0.2 
 
Table 23 Zeta potential of the different apatitic substrates after BP adsorption as a function of risedronate content [186]. 
 Zeta 
potential 
(mV) 
BP 
(wt.%) 
BP 
(µmol/m
2
) 
BP 
(μmol/g) 
HABP -12.9 1.2 1.8 41.2 
HAPEIBP  +23.5 5.0 6.0 156 
ZnHABP -13.9 3.7 1.15 98.9 
ZnHAPEI 
 
+27.6 4.8 1.5 118 
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XRD analysis of the solid products obtained after bisphosphonate adsorption show that the presence of 
risedronate does not provoke precipitation of any other crystalline or amorphous phase and does not 
influence the crystallinity of the apatitic samples (Figure 63). In the insets, the order of plotting has been 
reversed in order to highlight possible dissimilarity. 
 
 
Figure 63 XRD patterns of apatitic samples before (black) and after (red) the adsorption process (Risedronate solution at 3 
mM) [186]. 
 
Similarly, TEM images of HABP, HAPEIBP, ZnHABP, ZnHAPEIBP show that the different apatitic 
substrates preserve their initial morphology after risedronate adsorption, as it can be appreciated by 
comparing the images reported in Figure 59 with those in Figure 64. Adsorption of BP provokes a slight, but 
appreciable, decrease of the values of zeta potential (Table 23).  
ZnHAPEI 
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Figure 64 TEM images of the different solid apatite samples obtained after BP risedronate adsorption. 
 
Raman spectra of all apatitic supports after adsorption (Figure 66 and 67) show the characteristic vibration 
bands of the apatitic structure [232], those of the apatitic phosphate groups: ν2 (460 cm
-1), ν4 (590-610 cm
-1
), 
ν1 (960 cm
-1), ν3 (1000-1070 cm
-1
), the OH vibration band at 3560 cm
-1
 [226], and additional bands which 
can be attributed to the presence of adsorbed BP. In particular, two bands between 2900 and 3000 cm
-1
, 
corresponding to C-H stretching, and two intense bands between 1025-1055 cm
-1
, which might be assigned 
to C-H pyridine ring deformation, are present. Moreover, the spectra show medium intensity bands between 
1500-1600 cm
-1
, associated with the substituted pyridine ring, and the characteristic Raman bands of 
phosphonate groups between 850-1230 cm
-1
. Interestingly, we can see that these bands are shifted compared 
to those of risedronate sodium salt, indicating a change in the environment of these groups after adsorption. 
These spectroscopic observations suggest a strong interaction between risedronate molecule and calcium 
ions at the surface of the apatitic samples after adsorption, as no insoluble calcium salts was observed by 
XRD and SEM observations. These results are in accordance with the Langmuir model proposed for the 
adsorption isotherm, and the mechanism of interaction based on ion exchange process.  
A shift of the characteristic bands of risedronate is also observed in the Raman spectrum of HAPEIBP and 
ZnHAPEIBP after adsorption (Figure 67), which confirms that the process of adsorption of BP on the 
mineral part of HAPEI is similar. Moreover the presence of the vibration bands of PEI molecules (especially 
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stretching vibrations of CH, CH2 groups between 2800-3000 cm
-1
) on HAPEIBP and ZnHAPEIBP confirms 
that PEI is still present on HA surface. Thus, PEI is able to participate to the process of BP adsorption. 
 
 
Figure 65 Raman specta of Risedronate 
 
 
Table 24 Raman attributions of risedronate bands in the range 200-2000 cm-1. The letters indicate the band intensity: m 
(medium), w (weak), s (strong), sh (shoulder) 
Attribution Wavenumbers (cm
-1
)  
δ C-C 276m, 320w 
ν C-P 629m, 661m 
ν C-C-O 823w 
δ (P-OH) 862m 
νs P-O(H) 932w,970m, 1033sh 
δ (C-H) pyridine 1024s, 1054s 
ν P=O 1222w 
δ (C-H) pyridine 1315m 
ν (C=N) 
ν (C=C) pyridine 
           1445w, 1569m,1625s,1637m 
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Figure 66 Raman spectra of risedronate sodium salt, HA, HABP and ZnHABP after adsorption (with Qads equal to the 
maximum value of the adsorption isotherm) [186]. 
 
Figure 67 Raman spectra of risedronate sodium salt, PEI, HAPEIBP and ZnHAPEIBP after adsorption (with Qads equal to 
the maximum value of the adsorption isotherm), in the range 2400-4000 cm-1. 
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5.5.3 Risedronate release 
In Figure 68 is reported the results of risedronate release from the different apatitic supports. The release was 
fast during the first hour and then slowed down, as observed in previous studies for several apatitic supports 
[225]. The observed significant differences in the quantity of risedronate released show that the type of 
support is a determinant parameter controlling BP release.  
Various mathematical models can be used to describe and correlate the mechanism of BP release from each 
support. In the present work, the release data were fitted using the Hixson-Crowell model, which assumes 
that the release rate is limited by the dissolution of the support, and the Higuchi and Korsmeyer-Peppas 
models which describe drug release as diffusion process [233].  
 
Figure 68 Risedronate (BP) released (wt%) from the different apatitic samples as a function of time. 
 
The Higuchi diffusion model is not sufficient to describe the risedronate release from HA and ZnHA (r
2 
= 
0.88 and 0.83 from HA and HAZn, respectively, Figure 69a), suggesting another mechanism involving 
mainly dissolution of the apatitic support [233]. Infact risedronate was slowly released from these apatitic 
supports because it was irreversibly bound by chemisorption but, at the same time, the release rate was also 
limited by support dissolution. Moreover, the higher BP release rate observed from ZnHA compared with 
HA can be attributed to its higher specific surface and solubility. 
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In contrast, polymeric matrix are usually governed by simple laws of diffusion (r
2 
= 0.98 for HAPEI, Figure 
69a) [233, 234], but the composite nature of the HAPEI suggests the involvement of a secondary 
mechanism: the fast release, observed during the first hour, is attributed to the release of the drug molecules 
associated to the organic phase by physisorption and the sequent slow release of BP is due to the dissolution 
of the apatitic phase. This more complex mechanism of release explains the higher quantity of drug delivered 
from HAPEI compared with that from HA and ZnHA. The case of ZnHAPEI samples is the most 
complicated to understand because no mathematical models can be applied (r
2
 is really small). In figure 69a, 
it is showed that the best data fitting is given using a diffusion model (r
2
=0.54). 
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Figure 69 Linear regression of (a) Higuchi model (% BP released = √t) and (b) Hixson–Crowell model (∛Qads - ∛QR = t with QR the 
quantity of BP released) for the release kinetics of risedronate from HA, HAZn, HAPEI and ZnHAPEI [186]. 
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5.5 Octacalcium phosphate and α-tricalcium phosphate as supports for Ag nanoparticles 
 
This study proposes new composite materials based on OCP and -TCP as supports for AgNPs, using 
polydopamine (PDA) as functionalizing and reducing agent. The well know antimicrobial properties of silver 
nanoparticles [235]  are used to resolve the relatively high risk of infections associated to medical devices, 
including CaPs based biomaterials. 
The experimental conditions to prepare PDA functionalized OCP and -TCP at increasing AgNPs contents 
have been optimized and the influence of the presence of silver nanoparticles on the antibacterial properties 
of the composite materials has been investigated. Moreover, bone cells response was tested using an in vitro 
model based on co-culture of mesenchymal stem and endothelial cells. 
  
SEM analysis performed on the samples after immersion in the solution containing dopamine shows a 
greater amount of the polymer onto -TCP porous particles than onto OCP flat crystals (Figure 70). 
However, PDA onto -TCP appears clustered into aggregates whereas it seems more spread in 
close contact with the large surface of OCP crystals. Moreover, the samples obtained after 
immersion for 18 h show a massive dopamine polymerization that occurs without a close 
relationship with the calcium phosphates. 
Thermogravimetric analysis was used to estimate the amount of PDA deposited on OCP and -TCP : the 
relative content of PDA was determined as difference between the total weight loss of 
functionalized samples and that of the pristine calcium phosphates. The data, reported in Table 25, 
indicate that the amount of deposited PDA increases with immersion time and is significantly 
higher onto -TCP than onto OCP. This information is in agreement with SEM images and can be 
correlated to the different morphology of the two calcium phosphates. 
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Figure 70 SEM images of (a-c) OCPd and (d-f) α-TCPd after immersion times of (a,d) 1, (b,e) 2 and (c,f) 18 h. 
 
. 
 
Figure 71 Thermogravimetric plots of the different samples. 
 
 
 
Deposition of silver nanoparticles was carried out on functionalized samples obtained using an immersion 
time of 2 h, as compromise to load a good amount of PDA and to avoid the presence of massive 
dopamine polymerization.  
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Table 25 Polydopamine content (determined through thermogravimetric analysis) of the different samples as a function of 
time. The values of contact angles and water absorption time are also reported. 
Substrate Time 
(h) 
PDA content 
 (wt %) 
Static Contact Angle 
  (°) 
Absorption 
time 
 (sec) 
OCP  - - 28 2 
OCP 1 <1 43 11 
OCP 2 2.1 45 >15 
OCP 18 10.4 65 >>15 
α-TCP  - - 23 1 
α-TCP 1 2.4 32 1 
α-TCP 2 6.5 53 3 
α-TCP 18 25.7 55 12 
 
 
The presence of PDA influences the values of contact angle and time required for water complete spreading 
on the surface, which increase with PDA content (Table 25). This finding is somewhat opposite to what 
usually verified in other studies where PDA deposition induces a decrease of the contact angle with respect 
to that of the support [236, 237]. However, at variance with the supports used in these studies, both OCP and 
-TCP are highly hydrophilic, in agreement with their low contact angles and water spreading times (Table 
25). The modest increase of the values of these parameters on increasing PDA could be ascribed to the less 
homogeneous surfaces of the composite samples due to the presence of the polymer. 
The XRD patterns of the PDA functionalized calcium phosphates after AgNPs deposition show the 
characteristic reflections of OCP and -TCP, respectively, together with reflections at about 38.1° and at 
about 44.5 ° of 2 corresponding to the most intense peaks of silver (Figure 72). The relative intensity of 
these reflections increases with the concentration of the AgNO3 solution used for the deposition. The 
presence of AgNPs onto the surface of functionalized OCP and -TCP is clearly appreciable also in the SEM 
images of the composite materials, as shown in Figure 73. 
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Figure 72 XRD patterns of the different samples. The relative intensity of this reflection increases on increasing the concentration 
of the silver nitrate solution. 
 
 
Figure 73 SEM images of (a) OCPdAg1, (b) OCPdAg5, (c) OCPdAg10, (d) α-TCPdAg1, (e) α-TCPdAg5, (f) α-TCPdAg10. 
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Table 26 Ag content (wt%) determined through AAS analysis in solid samples after immersion of OCPd and α-TCPd into solutions 
at different concentration of AgNO3 
 
 
 
 
 
 
 
 
 
 
 
The results of ICP analysis, reported in Table 26, indicate that the amount of AgNPs associated to OCPd and 
-TCPd increases with silver concentration in solution up to about 11.6 and 6.8 wt%, respectively. The 
greater deposition of AgNPs onto OCPd cannot be ascribed to a greater presence of PDA, since its content its 
smaller than on -TCPd, and it might be due to the morphology of huge plate-like crystals of octacalcium 
phosphate, which favors a more homogeneous deposition of PDA, and, as a consequence, of AgNPs.  
 
 
 
 
 
 
 
 
 
 
Samples Ag content 
(wt %) 
OCPdAg1 1.6 
OCPdAg5 8.2 
OCPdAg10 11.6 
α-TCPdAg1 0.8 
α-TCPdAg5 4.7 
α-TCPdAg10 6.8 
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5.6 Antiresorption implant coating based on calcium alendronate and octacalcium phosphate 
deposited by matrix assisted pulsed laser evaporation (MAPLE) 
 
 
The chemistry and the physic of a bone implant surface are fundamental for the good integration and the 
success of a synthetic implantation with the natural bone tissue.  
In this study, AL indicates the crystalline form of calcium alendronate monohydrate, which was obtained by 
calcium sequestration from octacalcium phosphate CaAL•H2O [210, 238].  In the crystal structure of CaAL · 
H2O the  molecules are arranged at the origin and center of the unit cell and are organized in a network 
interlinked along the c -axis, with the water molecule relatively far from the metal atom, 3.6 Å ( Figure 74 ). 
The calcium atom is coordinated to six oxygen atoms belonging to phosphonate groups in a distorted 
octahedral geometry, with distances in the interval 2.2÷2.7 Å and mean distances (2.4 Å) very close to Ca-O 
mean distances in OCP. 
Calcium alendronate, especially when associated to octacalcium phosphate (OCP), exhibits a remarkable 
inhibition of osteoclast proliferation and activity, whereas it enhances osteoblast differentiation [210]. 
 
 
 
Figure 74 a view of CaAL*H20 structure [210]. 
 
 
Using MAPLE technique to deposit thin films of OCP, at different contents of CaAL•H2O, on titanium (Ti) 
substrates,  it was explored the possibility to create coatings able to offer a suitable interface for bone tissues 
thanks to the presence of OCP, and to provide a local availability of BP. In fact, although metallic materials, 
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such as Ti, fulfill the requirements of a successful orthopaedic implant, in terms of strength, toughness and 
resistance to wear and corrosion [239], incomplete osteointegration and stress shielding are the main causes 
of bone implant failures [240]. Coating the metallic surface with a thin film of calcium phosphate improves 
implant fixation to hard tissues [241, 242].  
 
5.6.1 Characterization of the crystalline powders 
 
The amount of CaAL*H20 in the composite material was tailored varying the concentration of alendronate in 
solution in order to have,  in the final solid samples,  48 wt%  and 100 wt% of CaAL*H2O respectively in the 
sample AL8 and AL20. 
In agreement, the XRD patterns (Figure 75) show that in the sample AL8 are present both characteristic 
peaks of OCP and of CaAL*H2O whereas calcium alendronate monohydrate is the unique crystalline phase 
in the sample AL20. From a morphological point of view, SEM images show that  the sample AL8 is a 
mixture of big plate like crystals, characteristic of OCP, and of tiny long road-like crystals characteristic of 
CaAL*H2O. The sample AL20 presents only calcium alendronate monohydrate crystals (Figure 76). 
The FTIR absorption spectra reported in Figure 77 confirm the different composition of the samples. The 
spectrum of pure OCP displays the absorption bands in the regions 1100–1000 cm−1 and 630–450 
cm
−1
characteristic, respectively, of  PO4 stretching and bending. The bands in the range 1300 and1100 cm
−1
, 
and 960 and 840 cm
−1
, are characteristic of  HPO4
2-
 stretching [243]. The spectra of the sample AL20 show 
the absorption bands at 1135 and 1094 cm
−1
which are associated to O-P-O and C-C-O bond stretching, 
whereas the bands at 940–916 cm−1 are connected only to motion of O-H-O and H-O-P, while the 613–580 
cm
−1
 absorption bands are related to modes of the phosphate group [244].  The FTIR spectrum of AL8 
clearly indicates the contribution of both OCP and AL. 
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Figure 75 X-ray diffraction patterns of crystalline powders obtained at increasing AL concentration in solution [246]. 
 
 
 
Figure 76 SEM images of crystalline powders showing characteristic morphologies of the two component crystalline phases: 
OCP and CaAL•H2O [246]. 
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Figure 77  FT-IR spectra of thin coatings obtained after MAPLE transfer of different crystalline powders [246]. 
 
 
5.6.2 Structural and morphological characterization of the coatings 
 
The XRD patterns of the thin films confirm the data obtained by XRD analysis of the powder. At low angle, 
the X-ray diffraction pattern of cOCP thin film presents just the characteristic peak of OCP at 4.7° 2θ, 
whereas the XRD pattern of cAL20 shows just a peak at 9.1° 2θ, in agreement with the presence of 
CaAL•H2O as the unique crystalline phase. The contribution of both crystalline phases, OCP and 
CaAL•H2O, can be discriminated in the XRD pattern of cAL8. Similarly, the crystalline phases present in the 
different thin films can be identified also by FTIR absorption spectra (Figure 78), even if the absorption 
bands are generally less resolved with respect to those shown in the spectra of the corresponding powder 
samples. 
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Figure 78 X-ray diffraction patterns (a) and FT-IR spectra (b) of thin coatings obtained after MAPLE transfer of different 
crystalline powders [246]. 
 
AFM analysis was used to calculate the roughness parameter of the coatings. Roughness parameters, 
namely arithmetic mean roughness (Ra), root-square roughness(Rq), and the vertical distance 
between the highest and lowest points within the evaluation length (Rt), were recorded. The results 
indicate that there is no significant difference between the samples cOCP, cAL8, cAL20. Average values 
were: Ra = 0.211 ± 0.011  μm, Rq = 0.170 ± 0.007  μm, Rt = 1.288 ± 0.010  μm. 
The coating thickness was evaluated by profilometry using a stylus profiler XP2 from Ambios Technology. 
For this investigation, half of Ti substrate was shielded with tape during deposition in order to evaluate the 
level difference between top of the coating and uncoated Ti. A continuous scanning with 10 m s
−1
speed was 
used for depth evaluation from the top to the bottom of the coatings (Ti uncoated surface after tape removal). 
The result of the thickness measurement is similar in all the three samples and the value is around 100 nm.  
SEM images of the cOCP thin films display a quite homogeneous surface and the presence of crystal 
fragments, together with cauliflower-like aggregates and droplets, are evidently visible at higher 
magnification (Figure 79).  SEM images of cAL8 films show much smaller rod-like crystals, clearly 
discernible from the big plate-like crystals of pure OCP. These small crystals, which display the 
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characteristic morphology of CaAL•H2O [210], are the only ones which can be distinguished in SEM images 
of cAL20 thin films.  
 
 
Figure 79 SEM images of coatings displaying the characteristic morphologies of the two component crystalline phases – OCP 
and CaAL•H2O – after MAPLE transfer [246]. 
 
Calcium release test, in physiological solution, was performed to evaluate the degradation of the coatings. 
The results, reported in Figure 80, are in agreement with the different solubility of CaAL•H2O and OCP [61, 
245], and indicate that Ca release from cAL20 is about14 mg/L after 6 h and it increases up to about 18 mg/l 
at 2 days, after which it remains constant. Ca release from cOCP is much lower, whereas the amounts 
released from cAL8 assume intermediate values. 
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Figure 80 Calcium cumulative release from cOCP, cAL8 and cAL20 as a function of soaking time in physiological solution. 
Each value was determined in triplicate. The standard deviations do not exceed the size of the symbols [246]. 
 
The biological performance of the coatings was investigated through in vitro tests carried out using co-
cultures of osteoblast derived from stem cells and osteoclast derived from monocytes of osteoporotic 
subjects. 
The results show that the presence of calcium alendronate in the coatings dramatically inhibits 
proliferation, differentiation and activity of osteoporotic osteoclast. On the contrary, the 
bisphosphonate does not affect osteoblast viability, and it promotes their activity. Osteoblast 
differentiation is further enhanced when the coating is a composite of CaAL•H2O and OCP, most 
likely thanks to the good bioactivity of OCP. 
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6. Conclusions 
 
The aim of this PhD thesis was to develop new functionalized materials for the local treatment of bone 
diseases and to study the effects of ions and molecules on the synthesis, stability, crystal growth and 
structure of some of the most common calcium phosphates used for hard tissue repair, namely HA, 
OCP, DCPA and TCP. The functionalized agents taken into consideration include molecules from the 
family of Bisphosphonates (alendronate, zoledronate and risedronate), synthetic drugs with a well 
known anti-osteoporotic activity,  quercetin, which is a natural molecule present in several fruits and 
herbs and displays relevant anti-oxidant properties, and Silver nanoparticles to provide antibacterial 
properties. 
The adsorption and the release mechanisms of bisphosphonates on CaPs was investigated through the 
study of the interaction of risedronate with four different hydroxyapatite-based supports with 
modulated composition and surface charge.  The results of the study indicate that the isotherms of 
adsorption of risedronate on HA and on a partial Zn substituted apatite (ZnHA) were both 
Langmuirian in shape, but risedronate content on ZnHA at plateau was about twice with respect to 
HA, because of the higher specific surface of ZnHA.  The mechanism of adsorption can be explained 
by ionic exchange between bisphosphonate molecules in solution and phosphate on the surface of 
apatitic supports. HA and ZnHA positive surface charges were enhanced through functionalization of 
the apatitic phase with a polycationic polymer containing amino groups, polyethyleneimine (HAPEI 
and ZnHAPEI). The isotherm of adsorption of risedronate on HAPEI can also be described by the 
Langmuir model. The amount adsorbed at saturation was higher on HAPEI than on the other supports, 
but the plateau was not reached even at high equilibrium concentrations in solution. The ion exchange 
process proposed at the surface of the apatite seems to be affected by the presence of PEI. On the 
contrary, the isotherm of adsorption of risedronate on ZnHAPEI can be described by Freundlich 
model. Risedronate presents a lower affinity with the substrate ZnHAPEI compared to the other 
supports, which is testified also by the relative low quantity of adsorbed risedronate. Probably the 
simultaneous presence of zinc and polymer might affect the adsorption capacity. Similarly to the 
adsorption process, the risendronate release is related to the nature of the apatitic supports, as shown 
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by the higher amount of bisphosphonate released from HAPEI than from HA, ZnHA and ZnHAPEI 
substrates. Enhancement of positive charge on the surface of the HA nanocrystals, thanks to the 
presence of the polycationic polymer (PEI), promotes the adsorption of negatively charged BPs from 
solution and controls their release. Thus, it is possible to tailor risedronate adsorption and to control its 
release rate through modulation of the solubility and the chemical composition of the apatitic supports. 
Two different BPs, the powerful alendronate and zoledronate, were chosen to functionalize 
octacalcium phosphate (OCP), which is considered the precursor phase of biological apatites. The 
direct synthesis allows to get a single crystalline phase up to a zoledronate and alendronate content of 
3.5 and 5.2 wt%, respectively. The incorporation of both bisphosphonates provokes a slight decrease 
of the mean length of the coherent scattering domains, as well as morphological modifications that 
suggests a preferential interaction with the (0k0) faces of OCP. However, release data suggest a 
stronger interaction of ZOL than AL with OCP structure. The in vitro tests suggest that zoledronate 
and alendronate maintain their antiresorptive and anti-tumor properties even when incorporated into 
OCP. 
Alendronate in the form of calcium alendronate monohydrate (CaAL•H2O), obtained by calcium 
sequestration from octacalcium phosphate, was used also to deposit composite thin films on titanium 
substrates. Calcium alendronate monohydrate and calcium alendronate monohydrate/octacalcium 
phosphate as composite materials were transferred on the metallic surface by the Matrix-Assisted 
Pulsed Laser Evaporation (MAPLE) technique. The composite materials contained different amounts 
of CaAL•H2O, which were tailored by varying alendronate concentration in solution; the relative 
content of CaAL•H2O in the final solid samples amounts to 48 wt% for AL8 (the remaining 52 wt% is 
still OCP) and to 100 wt% for AL20. SEM images of the thin films deposited by MAPLE display a 
quite homogenous surfaces and evidence the presence of big plate-like crystals of OCP and much 
smaller rod-like crystals, characteristic of CaAL•H2O. The results indicate that MAPLE technique 
allows to develop implant coatings, which can provide not only a suitable interface for bone growth 
but also offer the availability of drugs able to prevent undesirable excessive bone resorption. 
Quercetin-functionalized HA was prepared following two different procedures: direct synthesis and 
through phase transition from monetite. Direct synthesis lead to functionalized nanocrystals containing 
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up to 3.1 wt% quercetin, which provoked a reduction of the crystals mean dimensions and of the 
length of the coherently scattering domains. The synthesis conditions provoked degradation of 
quercetin and, as a consequence, a significant reduction of its radical scavenging activity (RSA). 
Synthesis through phase transition yielded samples containing up to 1.3 wt% of quercetin incorporated 
into hydroxyapatite, with minor structural modifications. RSA values of these products reach levels of 
about 40% (pure quercetin exhibits RSA values varying from 45% to 50% as a function of 
concentration) confirming that the antioxidant activity of quercetin is maintained. These materials 
were submitted to in vitro cell tests using a tri-culture model, showing a positively influence on bone 
repair microenvironment and a stimulating effect on osteoblast proliferation and activity.  
The possibility to functionalize different calcium phosphate substrates with quercetin was also 
investigated through adsorption from solution. Interaction of quercetin with hydroxyapatite (HA), 
hydroxyapatite modified with alendronate (HAAL), monetite (DCPA) and strontium substituted 
monetite (SrDCPA) yielded samples with greater amounts of quercetin content, up to 6wt% in the case 
of HA. At variance with the results obtained through direct synthesis, the softer procedure conditions 
do not provoke any oxidation process, and the functionalized materials display high values of RSA.  
Finally, taking into account the relatively high risk of infections associated to medical devices, 
calcium phosphate based materials have been designed as supports for silver nanoparticles (AgNPs), 
using polydopamine (PDA) as functionalizing and reducing agent. The results of thermogravimetric 
analysis show that the amount of deposited PDA is significantly higher onto α-TCP (6.5 wt%) than 
onto OCP (2.1 wt%), as confirmed by SEM images. AgNPs deposition on the PDA functionalized 
calcium phosphates can be revealed through XRD analysis, since the diffraction patterns show the 
characteristic reflections of OCP and α-TCP and the most intense peaks of silver. The relative 
intensity of silver reflections increases with the concentration of the AgNO3 solution used for the 
deposition. ICP analysis indicates that the amount of AgNPs associated to OCPd and α-TCPd 
increases with silver concentration in solution up to about 11.6 and 6.8 wt%, respectively. The greater 
deposition of AgNPs onto OCP might be due to the morphology of huge plate-like crystals of 
octacalcium phosphate, which favors a more homogeneous deposition of PDA, and, as a consequence, 
of AgNPs. 
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Most of the materials developed in this PhD thesis have been submitted to biological in vitro tests, 
which generally indicated that the peculiar characteristics of the functionalized agents are maintained 
when incorporated into CaPs, so that these materials can be considered potential candidates for the 
local treatment of bone defects. 
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